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Role of the Chromatin Remodeling Domain in Definitive Hematopoietic Cells
Abstract
The zinc finger-encoding transacting factor EKLF, or erythroid Krüppel-like factor, binds key regulatory
elements of many erythroid-specific genes, and is essential for definitive erythropoiesis. Mice lacking this
factor die of anemia by E15.5 of gestation, failing to activate β-globin gene transcription, and
demonstrating a block in the erythroid differentiation program at the primitive erythroblast stage. In
contrast, megakaryocytic progenitors are amplified in EKLF-null embryos, with increased Fli-1 gene
expression, a marker of early megakaryocytic differentiation. These observations are consistent with the
idea that EKLF modulates the megakaryocytic-erythroid (M-E) differentiation switch.
Our laboratory has previously demonstrated that an amino terminal sequence of EKLF (D221EKLF) is
required to induce chromatin remodeling at the β-globin promoter in an EKLF-null erythroid cell line.
However, additional amino terminal sequences are required for initiation of β-globin gene transcription. To
evaluate the role of this chromatin remodeling domain in erythroid and megakaryocytic differentiation in
vivo, I have generated a knock-in allele of D221EKLF. Using the recombineering method, a lambda phagebased homolgous recombination method in E. coli, cDNA encoding theD221EKLF domain has been
inserted into the endogenous initiation site, thus placing the mutant protein under the cis-regulatory
elements of the endogenous murine EKLF locus. Subsequently, D221EKLF alleles have been generated by
gene targeting in ES cells. I have used the mice to probe the in vivo role of D221EKLF in definitive
hematopoietic cells.
Similar to EKLF-null embryos, mice homozygous for the D221EKLF mutant allele die of anemia by E15.5
of gestation. Molecular analysis ofD221EKLF erythroblasts reveals i) a failure to activate β-globin gene
transcription; ii) lack of GATA-1 and NF-E2 recruitment to the β-globin promoter; iii) a block in terminal
erythroid differentiation. In contrast to erythroid cells lacking EKLF, D221EKLF erythroid progenitors
demonstrate appropriate binding of the D221EKLF encoding domain to all EKLF-regulatory sequences
and a chromatin architecture and histone modification pattern at erythroid-specific genes that
recapitulate the events observed in wild-type EKLF erythroblasts at a similar stage of erythroid ontogeny.
Examining the role of D221EKLF in megakaryopoiesis, I observed inhibition of megakaryocytic progenitor
expansion in D221EKLF fetal hematopoietic cell populations when compared to EKLF-null embryos.
Molecular analysis of D221EKLF erythroblasts reveals i) binding of theD221EKLF mutant protein to the
Fli-1 promoter with inhibition of gene transcription; ii) hypoacetylation of histone H3 at the Fli-1 promoter;
iii) recruitment of a Sin3A-containing corepressor complex to the Fli-1 promoter. Taken together, my
results suggest strongly that the unique D221EKLF domain is sufficient to modulate the chromatinspecific roles of EKLF at erythroid- and megakaryocytic-specific loci in definitive hematopoietic cells in
vivo.
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ABSTRACT
The zinc finger-encoding transacting factor EKLF, or erythroid Krüppel-like
factor, binds key regulatory elements of many erythroid-specific genes, and is essential
for definitive erythropoiesis. Mice lacking this factor die of anemia by E15.5 of gestation,
failing to activate β-globin gene transcription, and demonstrating a block in the erythroid
differentiation program at the primitive erythroblast stage. In contrast, megakaryocytic
progenitors are amplified in EKLF-null embryos, with increased Fli-1 gene expression, a
marker of early megakaryocytic differentiation. These observations are consistent with
the idea that EKLF modulates the megakaryocytic-erythroid (M-E) differentiation switch.
Our laboratory has previously demonstrated that an amino terminal sequence of
EKLF (Δ221EKLF) is required to induce chromatin remodeling at the β-globin promoter
in an EKLF-null erythroid cell line. However, additional amino terminal sequences are
required for initiation of β-globin gene transcription. To evaluate the role of this
chromatin remodeling domain in erythroid and megakaryocytic differentiation in vivo, I
have generated a knock-in allele of Δ221EKLF. Using the recombineering method, a
lambda phage-based homolgous recombination method in E. coli, cDNA encoding the
Δ221EKLF domain has been inserted into the endogenous initiation site, thus placing the
mutant protein under the cis-regulatory elements of the endogenous murine EKLF locus.
Subsequently, Δ221EKLF alleles have been generated by gene targeting in ES cells. I
have used the mice to probe the in vivo role of Δ221EKLF in definitive hematopoietic
cells.
Similar to EKLF-null embryos, mice homozygous for the Δ221EKLF mutant
allele die of anemia by E15.5 of gestation. Molecular analysis of Δ221EKLF
erythroblasts reveals i) a failure to activate β-globin gene transcription; ii) lack of GATA1 and NF-E2 recruitment to the β-globin promoter; iii) a block in terminal erythroid
differentiation. In contrast to erythroid cells lacking EKLF, Δ221EKLF erythroid
progenitors demonstrate appropriate binding of the Δ221EKLF encoding domain to all
EKLF-regulatory sequences and a chromatin architecture and histone modification
pattern at erythroid-specific genes that recapitulate the events observed in wild-type
EKLF erythroblasts at a similar stage of erythroid ontogeny.
Examining the role of Δ221EKLF in megakaryopoiesis, I observed inhibition of
megakaryocytic progenitor expansion in Δ221EKLF fetal hematopoietic cell populations
when compared to EKLF-null embryos. Molecular analysis of Δ221EKLF erythroblasts
reveals i) binding of the Δ221EKLF mutant protein to the Fli-1 promoter with inhibition
of gene transcription; ii) hypoacetylation of histone H3 at the Fli-1 promoter; iii)
recruitment of a Sin3A-containing corepressor complex to the Fli-1 promoter. Taken
together, my results suggest strongly that the unique Δ221EKLF domain is sufficient to
modulate the chromatin-specific roles of EKLF at erythroid- and megakaryocytic-specific
loci in definitive hematopoietic cells in vivo.

vi

TABLE OF CONTENTS
CHAPTER 1: INTRODUCTION ........................................................................................1
MOUSE HEMATOPOIESIS .........................................................................................1
Overview of erythropoiesis ......................................................................................1
Overview of megakaryopoiesis................................................................................3
Transcription factors in erythropoiesis and megakaryopoiesis ................................3
ERYTHROID KRÜPPEL-LIKE FACTOR ..................................................................5
Discovery of EKLF in MEL cell line ......................................................................5
Molecular properties of EKLF .................................................................................5
Expression of EKLF ................................................................................................7
Regulation of EKLF.................................................................................................7
The role of EKLF at the β-globin locus ...................................................................8
Other EKLF target genes .........................................................................................9
EKLF possesses distinct and separable chromatin remodeling and
transactivation domains .........................................................................................10
PROJECT OUTLINE ..................................................................................................12
CHAPTER 2: GENERATION OF A KNOCK-IN ALLELE OF EKLF UTLIZING
RECOMBINEERING TECHNOLOGY ...........................................................................14
INTRODUCTION .......................................................................................................14
MATERIALS AND METHODS .................................................................................16
BAC transfer into recombinogenic strains .............................................................16
Plasmids .................................................................................................................16
Recombineering .....................................................................................................17
Excision of the NEO cassette in bacteria ...............................................................17
Gene targeting in ES cells and generation of Δ221EKLF mice.............................18
Mouse genotyping ..................................................................................................18
Husbandry of mice .................................................................................................18
Analysis of peripheral blood counts ......................................................................19
Primers ...................................................................................................................19
RESULTS ....................................................................................................................19
Generation and characterization of targeting vectors ............................................19
Targeting of the murine EKLF genomic locus ......................................................28
Δ221EKLF heterozygous mice are phenotypically normal ...................................28
DISCUSSION ....................................................................................................................31

vii

CHAPTER 3: CHARACTERIZATION OF THE MOLECULAR
CONSEQUENCES OF Δ221EKLF EXPRESSION IN VIVO ..........................................38
INTRODUCTION .......................................................................................................38
MATERIALS AND METHODS .................................................................................39
RNA analysis .........................................................................................................39
Protein analysis ......................................................................................................40
Cytospins, sections, and staining ...........................................................................41
DNase I sensitivity assays ......................................................................................41
Chromatin immunoprecipitation assays .................................................................42
RESULTS ....................................................................................................................43
Δ221EKLF homozygous animals die in utero and exhibit ineffective
erythropoiesis .........................................................................................................43
Δ221EKLF is expressed in fetal liver ....................................................................47
Expression of Δ221EKLF is sufficient for β-globin promoter remodeling ...........52
Expression of Δ221EKLF induces histone modifications at the β-globin
promoter .................................................................................................................52
Δ221EKLF binds to erythroid-specific gene loci ..................................................56
Expression of Δ221EKLF is insufficient for high-level β-globin transcription ....56
Differential binding of factors at the β-globin LCR and promoter ........................56
DISCUSSION ..............................................................................................................62
Expression of Δ221EKLF is not sufficient to rescue the EKLF-null phenotype...62
Expression of Δ221EKLF is sufficient for nucleosomal remodeling and histone
modifications in vivo ..............................................................................................62
Nucleosomal remodeling and histone modification are not sufficient for
recruitment of erythroid-specific transcription factors to the β-globin promoter
and activated β-globin transcription ......................................................................64
A model for Δ221EKLF in β-globin promoter remodeling ...................................65
CHAPTER 4: EXPRESSION OF Δ221EKLF RESULTS IN ALTERED
ERYTHROID MATURATION AND BLOCKED MEGAKARYOCYTIC
EXPANSION .....................................................................................................................68
INTRODUCTION .......................................................................................................68
MATERIALS AND METHODS .................................................................................70
Mice ......................................................................................................................70
Colony-forming assays ..........................................................................................70
FACS analysis ........................................................................................................71
Globin gene expression by real time RT-PCR .......................................................71
Chromatin immunoprecipitation assays .................................................................71
viii

RESULTS ....................................................................................................................72
Expression of Δ221EKLF alters erythroid differentiation and inhibits
expansion of megakaryocytic progenitors .............................................................72
Δ221EKLF alters expression of non-β-globin-like erythroid-specific genes ........74
A role for Δ221EKLF in megakaryopoiesis and regulation of Fli-1 .....................74
A repressor complex is recruited to the Fli-1 promoter in Δ221EKLF cells .........80
DISCUSSION ..............................................................................................................80
Failure of erythroid differentiation in Δ221EKLF-expressing cells ......................80
Δ221EKLF regulates Fli-1 gene and inhibits expansion of megakaryocytic
progenitors in vivo..................................................................................................82
Δ221EKLF uniquely inhibits Fli-1 by recruitment of a Sin3A-containing
corepressor complex ..............................................................................................83
CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS.............................................85
Δ221EKLF mice are an excellent model to study separable chromatin remodeling
and β-globin gene transcription in vivo........................................................................85
What is the role of Δ221EKLF in erythroid-specific transcription factories? .............86
Is Δ221EKLF sufficient for formation of the Active Chromatin Hub (ACH)? ...........86
Does Δ221EKLF regulate other megakaryocytic genes in vivo?.................................87
LIST OF REFERENCES ...................................................................................................89
APPENDIX: SUPPORTING FIGURES AND TABLES ...............................................104
VITA ................................................................................................................................115

ix

LIST OF TABLES
Table 2.1

Predicted fragment size with restriction enzyme digestion .......................27

Table 2.2

Genotyping of adult animals from heterozygous matings .........................32

Table 2.3

Complete blood count analysis of Δ221EKLF heterozygous
adult mice ...................................................................................................33

Table 3.1

Genotyping of embryos at different stages of gestation from
heterozygous matings.................................................................................44

Table 3.2

Quantitative analysis of benzidine-positive E14.5 fetal liver
erythroblasts ...............................................................................................46

Table A.1

Putative EKLF-dependent genes..............................................................105

Table A.2

Predicted fragment size with restriction enzyme digestion .....................108

Table A.3

Buffer composition used in ChIP analysis ...............................................110

Table A.4

Primers used for ChIP analysis ................................................................111

Table A.5

Primers used for real time RT-PCR analysis ...........................................112

x

LIST OF FIGURES
Figure 1.1

Overview of murine hematopoiesis .............................................................2

Figure 1.2

Domain mapping of murine EKLF ..............................................................6

Figure 1.3

Separable chromatin remodeling and transactivation domains
of EKLF ....................................................................................................11

Figure 2.1

Overview of the recombineering method used to generate vectors
for targeting in ES cell ...............................................................................20

Figure 2.2

Mapping of the gap-repaired plasmid ........................................................22

Figure 2.3

Analysis of Δ221EKLF mini-targeting vector ...........................................24

Figure 2.4

Verification of the final targeting vector using restriction enzyme
analysis.......................................................................................................26

Figure 2.5

Targeting of cDNA encoding HA-∆221EKLF into the endogenous
EKLF locus ................................................................................................29

Figure 2.6

Identification of heterozygous mice expressing HA-∆221EKLF ..............30

Figure 2.7

Normal circulating erythrocytes in Δ221EKLF heterozygous
adult animals ..............................................................................................34

Figure 3.1

Δ221EKLF embryos are anemic ................................................................45

Figure 3.2

Defects in cell shape and content in Δ221EKLF fetal liver
erythroblasts ...............................................................................................46

Figure 3.3

Accumulation of hemosiderin in fetal liver of mice expressing
Δ221EKLF .................................................................................................48

Figure 3.4

Expression of Δ221EKLF in fetal liver .....................................................49

Figure 3.5

Localization of Δ221EKLF knock-in protein ............................................51

Figure 3.6

DNase I sensitivity at the β-globin promoter in Δ221EKLF fetal liver
erythroblast ................................................................................................53

Figure 3.7

Global acetylation of histone H3 across the β-globin locus ......................54

Figure 3.8

Trimethylation pattern at lysine 4 of histone H3 .......................................55
xi

Figure 3.9

Differential binding of Δ221EKLF to erythroid-specific gene loci ...........57

Figure 3.10

Lack of β-globin transcripts in Δ221EKLF fetal liver erythroblasts
in vivo .........................................................................................................58

Figure 3.11

Lack of RNA polymerase at the β-globin promoter in Δ221EKLF
expressing cells ..........................................................................................60

Figure 3.12

Binding of erythroid-specific transcription factors at the β-globin
promoter in vivo .........................................................................................61

Figure 3.13.

Models of β-globin promoter remodeling in erythroid cells......................66

Figure 4.1

Potential models of EKLF-mediated repression of megakaryopoiesis ......69

Figure 4.2

Effects of Δ221EKLF expression on terminal erythroid differentiation
and proliferation of fetal liver progenitor cells ..........................................73

Figure 4.3

Altered pattern of erythroid-specific gene expression in Δ221EKLF
fetal liver erythroblasts ..............................................................................75

Figure 4.4

Blocked expansion of megakaryocytic progenitors in Δ221EKLF
mice ............................................................................................................77

Figure 4.5

Differential expression of β-globin and Fli-1 gene in Δ221EKLF
expressing cells ..........................................................................................78

Figure 4.6

Distinct regulation of β-globin and Fli-1 promoters in Δ221EKLF
fetal liver erythroblasts ..............................................................................79

Figure 4.7

Recruitment of a Sin3A-containing repressor complex .............................81

Figure 4.8

Modified potential models of Δ221EKLF-mediated repression
of megakaryopoiesis ..................................................................................84

Figure A.1

Confirmation of the mini-targeting vectors .............................................107

Figure A.2

Sequences of Southern blot probes used in screening targeted ES
cells and genotyping of animals ...............................................................109

Figure A.3

Fetal liver hematopoietic progenitors ......................................................114

xii

LIST OF ABBREVIATIONS
ACH
AHSP
ALAD
ALAS2
AMP
APC
BAC
BFU-E
BKLF
cDNA
CFU
CFU-E
CFU-GEMM
CFU-GM
CFU-MK
ChIP
CLP
CMP
COOH
CPOX
Da
DAPI
dsDNA
DT
EKLF
En-1, En-2
EPB4.9
E-RC1
ES
FECH
FITC
FOG1
GAL4
H&E
HA
HCT
HGB
HS
HSC
IP
IVR
kDa

Active Chromatin Hub
Alpha Hemoglobin Stabilizing Protein
Aminolevulinate Dehydratase
Aminolevulinic Acid Synthase 2
Ampicillin
Allophycocyanin
Bacteria Artificial Chromosome
Burst Forming Unit-Erythroid
Basic Krüppel-like Factor
Complementary DNA
Colony Forming Unit
CFU-Erythroid
CFU-Granulocyte-Erythroid-MonocyteMegakaryocyte
CFU-Granulocyte-Macrophage
CFU-Megakaryocyte
Chromatin Immunoprecipitation
Common Lymphoid Progenitor
Common Myeloid Progenitor
Carboxyl
Coproporphyrinogen Oxidase
Dalton
4',6-Diamidino-2-Phenylindole
Double-stranded DNA
Diptheria Toxin
Erythroid Krüppel-like Factor
Engrailed
Erythroid Protein Band 4.9
EKLF Coactivator-Remodeling Complex 1
Embryonic Stem
Ferrochelatase
Fluorescein Isothiocyanate
Friend of GATA-1
Galactose 4
Hematoxylin and Eosin
Hemagglutinin
Hematocrit
Hemoglobin
Hypersensitive Site
Hematopoietic Stem Cell
Immunoprecipitation
Intervening region
KiloDalton
xiii

KO
LB
LCR
LMO2
Lys
MEL
MEP
mRNA
Myf5
NEO
NF-E2
NH2
NLS
PAC
PBGD
PCR
PE
PGK
PLT
PMSF
PolII
PPOX
RBC
RT-PCR
SCL
SDS-PAGE
SEM
shRNA
TF
TK
UROD
WBC
WT

Knock-out
Luria Broth
Locus Control Region
LIM Domain Only 2
Lysine
Mouse Erythroleukemic
Megakaryocyte-Erythrocyte Progenitor
Messenger RNA
Myogenic factor 5
Neomycin
Nuclear Factor – Erythroid 2
Amino
Nuclear Localizing Signal
P1 Artificial Chromosome
Porphobilinogen Deaminase
Polymerase Chain Reaction
Phycoerythrin
Phosphoglycerate Kinase
Platelet Count
Phenylmethylsulphonyl Fluoride
Polymerase II
Protoporphyrinogen Oxidase
Red Blood Count
Reverse Transcriptase Polymerase Chain Reaction
Stem Cell Leukemia
Sodium Dodecyl Sulfate Polyacrylamide Gel
Electrophoresis
Standard Error Mean
Short Hairpin RNA
Transcription Factor
Thymidine Kinase
Uroporphyrinogen Decarboxylase
White Blood Count
Wild Type

xiv

CHAPTER 1: INTRODUCTION
MOUSE HEMATOPOIESIS
Hematopoiesis is the formation and development of blood cells involving the
differentiation of a multipotent progenitor, the hematopoietic stem cell (HSC), and its
progeny into all blood cell lineages (Figure 1.1) (Orkin & Zon, 2008). This complex
continuous process requires a broad spectrum of lineage-specific transcription factors
(TFs), such as SCL, LMO2, c-myb, PU.1, EKLF, GATA-1, NF-E2, and Fli-1 (Shivdasani
& Orkin, 1996; Perry & Soreq, 2002; Orkin & Zon, 2008). Genetic studies involving the
disruption or over-expression of these genes have facilitated our understanding of the
transcriptional regulation of hematopoiesis (Perry & Soreq, 2002). Many of these TFs
are beyond the scope of my dissertation and will not be addressed. In the context of this
dissertation, I will explore the role of erythroid-Krüppel-like factor, or EKLF, in β-globin
gene regulation during erythroid differentiation (Chapter 3). Furthermore, I will
demonstrate that the chromatin remodeling encoding domain of EKLF is sufficient to
repress expansion of megakaryocytic progenitors observed with complete loss of EKLF
(Chapter 4).
Overview of erythropoiesis
Erythropoiesis is the development of mature red blood cells from hematopoietic
stem cells (Orkin & Zon, 2008). In mammals, this process occurs in the bone marrow
and is characterized by three stages (Palis, 2009). The first stage involves production of
lineage –committed progenitors. The earliest recognizable erythroid-specific progenitor
is the burst-forming unit erythroid (BFU-E). The BFU-E generates more mature
erythroid-committed progenitors termed colony-forming units erythroid (CFU-E)
(Socolovsky et al., 1998). BFU-E and CFU-E can be detected in vitro using colonyforming assays (Ogawa et al., 2002). The second stage of erythroid differentiation
consists of the progression of erythroid precursors from early proerythroblasts into
orthochromatic erythroblasts. This stage of erythroid differentiation is characterized by
the progressive accumulation of hemoglobin, expansion of erythroblasts, and progressive
nuclear pyknosis and ultimately loss of the nucleus. The final stage of erythropoiesis
involves maturation of the young red blood cells (reticulocytes) into mature circulating
red cells (Palis, 2009).
Erythropoiesis occurs in distinct phases and anatomic sites during murine
development (Dzierzak & Medvinsky, 1995; Zon, 1995; Shivdasani & Orkin, 1996; Palis,
2008). The first phase can be identified in the yolk sac at embryonic day 7.5 (E7.5) in
mice and is referred to as primitive or embryonic erythropoiesis. Primitive erythrocytes
are large cells that retain their nuclei and produce embryonic globin chains (ζ, ε/βh1).
The adult β-globin genes are silent. By E11, definitive erythropoiesis is initiated in the
fetal liver. At this stage, the adult globin (α, βmaj/βmin) genes are expressed and the
embryonic globin genes are silenced. The molecular mechanisms regulating the
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Figure 1.1. Overview of murine hematopoiesis. All blood cell types arise from the
self-renewing hematopoietic stem cell (HSC) that differentiates into committed
progenitor cells to produce mature blood cells. The erythroid and megakaryocytic
lineage is thought to have come from a common bipotent progenitor (megakaryocyticerythroid progenitor (MEP) (dotted box). The MEP population is thought to be formed
from common myeloid progenitor (CMP); recent evidence proposes a direct pathway
from HSCs to MEP (dotted line). Key transcription factors regulating this process are
listed by the cell type in which they are expressed. Abbreviations: MPP, multipotent
progenitor; CLP, common lymphoid progenitor; GMP, granulocyte and macrophage
progenitor; CFU-G, colony-forming unit granulocyte; CFU-M, colony-forming unit
monocyte/macrophage; BFU-E, blast-forming unit erythrocyte; CFU-E, colony-forming
unit erythrocyte; MK-P, megakaryocyte progenitor.
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switching of globin gene expression has been the intense focus of many laboratories.
They have provided a critical foundation for our understanding of the molecular
mechanism underpinning erythropoiesis.
Overview of megakaryopoiesis
The erythroid and megakaryocyte lineages are thought to be derived from a
common precursor, the bipotent megakaryocyte-erythroid progenitor (MEP) (Debili et al.,
1996). In the most established pathway, HSCs generate common myeloid progenitor
(CMP) cells from which the MEP is formed (Akashi et al., 2000). However, it has been
recently proposed that HSCs can give rise to MEP population without an intermediate
progenitor (Adolfsson, 2005).
Megakaryopoiesis is the process by which HSCs differentiate into mature
megakaryocytes through a series of differentiated progenitors. Megakaryocytic
progenitors are detected in the yolk sac and fetal liver at approximately E7.5-10.5 and
E11.5, respectively (Tober et al., 2007). The earliest committed MK progenitor is the
burst-forming unit megakaryocyte (BFU-MK) that gives rise to the more mature colonyforming unit megakaryocyte (CFU-MK) (Briddellet al., 1989). The CFU-MK then gives
rise to megakaryoblasts that in turn differentiate into mature megakaryocytes.
Transcription factors in erythropoiesis and megakaryopoiesis
The precursor cells express many common hematopoietic transcription factors
that are essential to both erythropoiesis and megakaryopoiesis, including GATA-1
(Pevny et al., 1995; Shivdasani et al., 1997), FOG1 (Tsang et al., 1997), and SCL (Hall et
al., 2003). The MEP lineage differentiation is regulated in part by the differential
expression and combinatorial action of these transcription factors.
GATA-1
GATA-1, the founding member of the GATA family of zinc finger proteins, is an
erythroid transcription factor that binds to the DNA sequences WGATAR found at the
cis-regulatory sequences of nearly all erythroid genes, including the β-globin gene
(Martin & Orkin, 1990; Weiss & Orkin, 1995). GATA-1 is also expressed and has
defined functional activities in megakaryocytes, eosinophils, and mast cells (Zon et al.,
1993). Hemizygous deletion of GATA-1, located on the X-chromosome, leads to loss of
erythropoiesis and embryonic lethality by E11.5 (Fujiwara et al., 1996). GATA-1 null
mice also display a block in megakaryocyte development. However, GATA-1 null ES
cells can develop into other hematopoietic lineages (Kitajima et al., 2006). Similarly,
forced expression of GATA-1 in an early myeloid cell line promotes megakaryocytic
differentiation, suggesting that GATA-1 has a key role in lineage determination
(Shivdasani & Orkin, 1996; Shivdasani et al., 1997). Studies to identify proteins that

3

bind to GATA-1 led to the discovery of Friend of GATA (FOG-1), a nuclear zinc finger
protein that binds the amino zinc finger of GATA-1 (Tsang et al., 1997). Expression of
FOG-1 is similar to that of GATA-1. Like mice lacking GATA-1, FOG-1 null mice do
not form megakaryocytic progenitors and are embryonic lethal at E11.5 (Tsang et al.,
1998).
NF-E2
NF-E2 is a hematopoietic transcription factor belonging to the basic-leucine
zipper family of dimeric proteins consisting of a ubiquitously expressed 18 kDa subunit
and a tissue-specific 45 kDa subunit (Chan et al., 1993). Initial studies in cell lines
provided evidence that NF-E2 is essential for β-globin gene expression (Lu et al., 1994).
Surprisingly, mice lacking the 45 kD hematopoietic-restricted subunit develop only a
mild erythroid phenotype, but exhibit severe thrombocytopenia with bone marrow
showing excessive immature and dysplastic megakaryocytes (Shivdasani & Orkin, 1995).
The subtle effects on erythroid maturation are presumably due to functional redundancy
between NF-E2 and other basic leucine zipper family proteins (Sawado et al., 2001). By
contrast, the molecular basis for the severe defects in megakaryocyte differentiation and
platelet release remains to be elucidated.
Fli-1
Fli-1 is a member of the Ets family of transcription factors (Watson et al., 1992)
containing a conserved winged helix-loop-helix DNA binding (ETS) domain which has
critical functions in development and oncogenesis (Jackers et al., 2004). Fli-1 is
preferentially expressed in cells of the hematopoietic lineages and vascular endothelium.
Fli-1 has been shown to transcriptionally activate many genes, including those involved
in megakaryopoiesis. In undifferentiated hematopoietic cell lines, overexpression of Fli1 can induce megakaryocytic features and inhibit erythroid differentiation (Pereira et al.,
1999; Athanasiou et al., 2000). Moreover, Fli-1 knock-out mice either have abnormal
megakaryocytes with associated thrombocytopenia (Hart et al., 2000) or fail to develop
recognizable megakaryocytes (Kawada et al., 2001). These observations are consistent
with the idea that Fli-1 is a key factor in the lineage fate decision leading to the
production of megakaryocytes.
Interestingly, these factors are interconnected with my gene of interest, EKLF
(reviewed in a separate section below). EKLF, GATA-1, and Fli-1 are all expressed in
the MEP (Orkin & Zon, 2008). GATA-1 transcriptionally activates EKLF (Crossley et
al., 1994), while Fli-1 and EKLF interactions have been noted (Starck et al., 2003).
Moreover, recent data including that from our laboratory suggest that EKLF represses
Fli-1 expression (J.M.C unpublished data; Frontelo et al., 2007). Similarly, both EKLF
and NF-E2 are essential for high level β-globin gene transcription (Asano &
Stamatoyannopoulos, 1998; Sawado et al., 2001). However, the relationship between
EKLF and NF-E2 in megakaryopoiesis is relatively unknown. Although associations
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between these transcription factors and many others are recognized in erythroid and
megakaryocytic differentiation, the mechanisms underlying these relationships have yet
to be resolved.
ERYTHROID KRÜPPEL-LIKE FACTOR
Discovery of EKLF in MEL cell line
The murine erythroleukemia (MEL) cell line has proven a popular and highly
important murine model system to study erythroid-specific gene expression. These
erythroid progenitor cells, immortalized by infection with Friend virus (Friend, 1957;
Antoniou, 1991), are arrested at the proerythroblast stage of development. This cell can
be maintained in tissue culture indefinitely (Friend, 1957; Antoniou, 1991). However,
upon treatment with various chemical agents, MEL cells can be induced to undergo
erythroid differentiation with the induction of globin and other erythroid genes involved
in the terminal erythroid differentiation program (Marks & Rifkind, 1988; Radhika et al.,
1995). These cells have also proven to be useful to study megakaryocytic differentiation
(Bouilloux et al., 2008).
This transformed cell line is an ideal model to identify novel genes which may
play a role in erythropoiesis. Using subtractive hybridization and enriching for genes
expressed in a MEL cell line, but not in a murine monocyte-macrophage cell line, a novel
erythroid cell-specific zinc finger protein was isolated (Miller & Bieker, 1993). Close
inspection of the zinc finger region of this factor revealed that it is similar to the
Drosophila pattern-determining gap gene Krüppel. Therefore, the protein was named
EKLF/KLF1, for erythroid Krüppel-like factor (Miller & Bieker, 1993).
Molecular properties of EKLF
EKLF maps to a region on mouse chromosome 8 (Jenkins et al., 1998) and human
chromosome 19 (Bieker, 1996; van Ree et al., 1997). The EKLF gene spans ~6.5 kb and
contains 3 exons. There are two major transcripts produced, the results of alternative
transcriptional start sites at nucleotides 41 and 55. This is not uncommon as multiple
transcription start sites have been observed for other tissue-specific genes, namely the
heterogeneous 5’ ends of both c-myb and GATA-1 (Bender & Kuehl, 1986; Tsai et al.,
1989). Sequence analysis reveals open reading frames beginning at the in-frame
methionines 1 and 19. Because methionine 1 does not match the Kozak consensus
sequence, translation of the major product starts from methionine 19, encoding an EKLF
protein of 358 amino acids (37,755 Da) (Miller & Bieker, 1993). The protein has a
carboxy-terminal DNA-binding domain consisting of three C2H2 zinc fingers and a
proline-rich amino domain that has structural similarities to other transactivation domains
(Figure 1.2).
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Figure 1.2. Domain mapping of murine EKLF. This schematic diagram summarizes
the EKLF protein showing its transactivation (amino terminal) and DNA binding
(carboxyl terminal) regions. EKLF encodes a protein of 376 amino acids characterized
by a proline-rich transactivation domain. The DNA binding domain contains three C2H2
zinc fingers. Also noted in the diagram are the locations of important phosphorylation
(T41), sumoylation (K74), acetylation (K288 and K302), and ubiquitination (throughout
protein) sites, and two NLS discussed in the text.
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EKLF/KLF1, the founding member of a 15 gene clade, interacts with the DNA
consensus sequence CCNCNCCCN found at many promoters (Miller & Bieker, 1993).
EKLF has two nuclear localization signals (NLSs) corresponding to a region adjacent to
the zinc finger DNA binding domain within a stretch of highly basic amino acids 275-296
(Quadrini & Bieker, 2002) and another more efficient signal within the zinc finger
domain itself encompassing amino acids 293-376 (Pandya & Townes, 2002; Quadrini &
Bieker, 2002). Interestingly, each zinc finger is important for the overall function of the
NLSs, and a complete zinc finger structure is necessary for efficient nuclear localization.
Expression of EKLF
Both human and murine EKLF have been cloned and show a high degree of
homology with >90% similarity in the zinc fingers and approximately 70% within the
proline-rich amino domain (Bieker, 1996; van Ree et al., 1997). Expression of both
factors is restricted to the erythroid lineage with high levels in murine and human
definitive hematopoietic progenitors (Miller & Bieker, 1993; Bieker, 1996; van Ree et al.,
1997). During in vitro hematopoietic cell differentiation of murine ES cells, EKLF is
expressed in the CMP and MEP population (Frontelo et al., 2007). EKLF expression is
absent in lymphoid cell lines (Miller & Bieker, 1993) and the CLP and their progeny
(Frontelo et al., 2007).
During murine ontogeny, EKLF is expressed early and at different anatomical
sites (Southwood et al., 1996). EKLF mRNA is detected first at the neural plate stage (at
E7.5) within the blood islands in the yolk sac. EKLF is then expressed within the hepatic
tissue beginning with the earliest stage of hepatic formation at E9 and continuing until
E14.5 when the liver becomes the only source of EKLF. Concomitantly with EKLF
mRNA, EKLF protein is also expressed in primitive cells and in the fetal liver. In the
adult animal, EKLF expression is strictly localized to the red pulp of the spleen.
Regulation of EKLF
EKLF is a stage-and lineage-specific transcription factor, its expression requiring
tight regulation. EKLF expression is induced by Bmp4/Smad signaling and GATA-1
(Adelmann et al., 2002; Lohmann & Bieker, 2008). However, regulation of EKLF
activity is achieved in part by post-translational modifications of the EKLF protein (see
Figure 1.2). First, EKLF is a phosphoprotein whose transcriptional activity is dependent
on the phosphorylation status at threonine 41 (T41) (Ouyang et al., 1998). On the other
hand, sumoylation of EKLF at lysine 74 (K74) promotes transcriptional repression of
megakaryopoiesis (Siatecka et al., 2007). Similarly, EKLF is acetylated by CBP/p300
(Zhang & Bieker, 1998; Zhang et al., 2001). This modification increases EKLF’s affinity
for the SWI/SNF components of chromatin remodeling complexes which has been
postulated to maintain chromatin in an open configuration (Armstrong et al., 1998;
Kadam et al., 2000; Zhang et al., 2001). On the other hand, EKLF acetylation can also
result in interaction with co-repressors Sin3A and recruitment of histone deacetylases
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(HDACs) to promoters to inhibit gene transcription (Chen & Bieker, 1996; Chen &
Bieker, 2004). Finally, EKLF can be ubiquitinated and degraded through the ubiquitinmediated proteosome pathway (Quadrini & Bieker, 2006).
The role of EKLF at the β-globin locus
Disruption of the EKLF gene by homologous recombination has demonstrated its
non-redundant role in erythropoiesis. EKLF-null embryos die of a lethal anemia by
embryonic day 16 (E16), as definitive erythroid cells fail to produce β-globin transcripts
in vivo (Nuez et al., 1995; Perkins et al., 1995), consistent with the idea that EKLF is
essential for β-globin gene transcription. However, it is now recognized that EKLF also
regulates expression of multiple erythroid-specific genes, including cytoskeletal proteins
(Nilson et al., 2006) and alpha hemoglobin stabilizing protein (AHSP) (Pilon et al., 2006).
Moreover, analysis of EKLF-null embryos that are transgenic for the human β-globin
locus confirmed the necessity of EKLF for human β-globin gene transcription (Perkins et
al., 1996; Wijgerde et al., 1996). Studies in EKLF-null animals have delineated three
mechanisms of action for EKLF in regulating β-globin gene transcription: i) chromatin
remodeling, ii) modulation of transactivation, and iii) stabilization of the locus control
region (LCR)/β-globin promoter interaction.
EKLF alters chromatin structure at the β-globin promoter
Local chromatin structure plays a critical role in regulating gene expression.
Transcriptionally active genes are typically found in regions of open chromatin structure
characterized by DNase I-sensitivity and histone hyperacetylation whereas inactive genes
are packaged in a highly condensed chromatin configuration that is typically DNase Iinsensitive and under-acetylated (Harju et al., 2002). Chromatin structure may be altered
by changing the organization of the nucleosome(s) at the gene promoter or by modifying
the histones (Harju et al., 2002). Thus, chromatin remodeling is an essential event for the
initiation of gene transcription in vivo.
EKLF is a key player in activating β-globin gene transcription. Not only has it
been postulated to be necessary for transactivation but it was the first factor implicated in
erythroid-specific promoter remodeling of the β-globin promoter. Analysis of EKLF-null
embryos revealed a specific loss of a developmentally specific DNase I hypersensitive
site in the proximal β-globin promoter (Wijgerde et al., 1996). Since the degree of
DNase I hypersensitivity of a given locus correlates with nucleosomal remodeling (Steger
& Workman, 1996; Pazin et al., 1997), these findings strongly suggest that EKLF is
required for chromatin reorganization at the β-globin promoter in definitive erythroid
cells. A loss of DNase I hypersensitivity was also observed in hypersensitive site 3
(HS3) of the LCR, but to a lesser extent. Furthermore, utilizing chromatin
immunoprecipitation (ChIP) analysis, we observed increased acetylation of histone H3 at
the β-globin promoter after induction of EKLF in an EKLF-inducible erythroid cell
system. This change correlates with activation of β-globin gene transcription (J.M.C
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unpublished data). These results confirmed the role of EKLF as a chromatin modulator
and transcriptional activator of the β-globin gene. However, the specific domains that
fulfill this role in vivo and the molecular mechanisms responsible for chromatin
modification remain to be elucidated.
EKLF-mediated transactivation
EKLF is an erythroid-specific transcription factor containing a carboxy-terminal
zinc finger DNA-binding domain and a proline rich amino terminal domain. Initial
structure-function studies, utilizing chimeric proteins consisting of the DNA-binding
domain of the yeast factor GAL4 fused in frame to various EKLF sequences, demonstrate
that the amino terminal region could be divided into two domains with opposing
functions (Chen & Bieker, 1996). In these assays, the first 104 amino acids activate
GAL4-dependent transcription, whereas an internal domain (aa 196-291) mediated
transcriptional repression. In contrast to these studies that utilize heterologous promoters,
our laboratory has shown that an internal domain of EKLF is sufficient for activation of
the endogenous β-globin promoter (Brown et al., 2002). However, it remains unclear
what functions of EKLF are required for β-globin gene transactivation in vivo.
The role of EKLF in LCR/β-globin promoter interaction
Regulation of the β-globin locus is believed to occur in part by competition of
each globin gene promoter for direct interaction with the LCR with the intervening region
looping out. Direct support for EKLF being involved in stabilizing the LCR/β-globin
promoter interaction was provided by utilizing chromosome conformation capture (3C)
technology (Dekker et al., 2002) to study the spatial organization of the β-globin locus.
In erythroid cells, the hypersensitive sites of the LCR are in close physical proximity to
the active globin genes with the intervening DNA sequence containing the inactive globin
genes looped out forming the Active Chromatin Hub (ACH), a nuclear compartment
dedicated to RNA polymerase II mediated transcription (Palstra et al., 2003). Subsequent
studies in EKLF-null fetal livers demonstrated that EKLF is required for ACH formation
and active β-globin gene transcription (Drissen et al., 2004). Despite the significant
insights into the binding sites, and the effects of wild-type EKLF action, it remains
unclear whether differing domains of EKLF are required for alteration of the β-promoter
and LCR architecture in vivo.
Other EKLF target genes
Early observations alluded to a broader role for EKLF in the regulation of genes
other than β-globin. First, the EKLF-null phenotype is more severe than that observed in
a murine model of β-thalassemia in which the adult β-globin genes are deleted by
homologous recombination (Ciavatta et al., 1995). Furthermore, enforced expression of
an EKLF-independent globin transgene fails to rescue the lethal phenotype (Perkins et al.,
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2000). Gene profiling studies by our laboratory and many others provide a list of
potential target genes (see Appendix Table A.1). Subsequent studies utilizing chromatin
immunoprecipitation (ChIP) analysis have confirmed dematin (Hodge et al., 2006),
AHSP (Keys et al., 2007; Pilon et al., 2006), ankyrin, Band 3 (Nilson et al., 2006), and
BKLF (Funnell et al., 2007) as direct EKLF target genes. Together these observations
support a broader role for EKLF in the regulation of other erythroid-specific genes and
provide additional evidence that defects in addition to β-globin deficiency contributes to
the lethal phenotype in EKLF-null mice.
EKLF possesses distinct and separable chromatin remodeling and transactivation
domains
To explore the determinants of EKLF-dependent β-globin gene activation, our
laboratory utilized an erythroblast cell line lacking endogenous EKLF expression,
J2eΔeklf (Coghill et al., 2001). Briefly, this line was prepared by immortalization of fetal
liver erythroblasts derived from E14.5 EKLF-null embryo by transduction with a raf/myc
retrovirus. Subsequently, the cells were transduced with retroviral constructs containing
EKLF cDNA fused in frame with the influenza hemagglutinin (HA) epitope at the amino
terminus and the tamoxifen-binding domain of the estrogen receptor (ERTM) at the
carboxyl terminus. Constructs containing full length human EKLF and a series of amino
terminal mutants were studied (Figure 1.3A) (Coghill et al., 2001; Brown et al., 2002).
Subsequently, these cell lines were utilized to study the distinct domains of EKLF in βglobin gene activation.
To determine the effects of the amino terminal deletions on formation of
hypersensitive sites at the β-globin promoter, nuclei of induced cells for each mutant
were incubated with increasing amounts of DNase I (Figure 1.3B). Contrary to an in
vitro study that demonstrated the DNA binding domain of EKLF alone could induce a
specific DNase I hypersensitive site of chromatinized β-globin template (Kadam et al.,
2001), the hypersensitive site pattern in J2eΔeklf cells expressing the Δ253EKLF mutant
is similar to that observed in J2eΔeklf null cells. In contrast, cells expressing Δ221EKLF
and Δ164EKLF show a hypersensitive site pattern similar to that observed with fulllength EKLF (flEKLF). Therefore, the sequence between aa 221-253 is required and
sufficient for an “open” configuration at the endogenous β-promoter (Brown et al., 2002).
Based on prior structural analysis of EKLF, the activation domain of EKLF
should reside in sequences upstream of the Δ221-253 regions. Our hypersensitive studies
suggested that the transcriptional and chromatin remodeling domain activities of EKLF
are separable. To test this hypothesis, transcriptional activity for each mutant was
measured by RNA protection assay and correlated with its chromatin remodeling
properties (Figure 1.3C). As anticipated, no significant level of the βmaj transcript was
detected in Δ253EKLF cells. In contrast, expression of the Δ221EKLF polypeptide
resulted in a small increase in gene transcripts. However, examination of cells expressing
Δ164EKLF revealed levels of βmaj transcripts that paralleled flEKLF expression. Thus,
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Figure 1.3. Separable chromatin remodeling and transactivation domains of EKLF.
(A) Schematic diagram of flEKLF retrovirus and derivative mutants used to stably
transduce J2e eklf cells. (B) The DNA binding domain (Δ253) is required but is not
sufficient for chromatin remodeling at the ßmaj globin promoter. Cells expressing each
EKLF mutant were cultured for 48 h in the presence of tamoxifen. Nuclei were isolated
and exposed to increasing concentrations of DNase I as previously described. DNA was
harvested, digested with EcoRI, and probed with a ßmaj-specific probe. The DNase I
concentration is 0 in the first lane of each panel and increases as shown by the shaded
triangle. (C) An internal domain of EKLF (Δ164) is sufficient to activate ß-globin gene
expression to wild-type levels. RNA was harvested from J2e eklf clones expressing
varying EKLF mutant moieties at 48 h post-tamoxifen induction RPA was performed
utilizing ßmaj and riboprobes. The numbers underneath the panel represent the mean fold
induction of the ß/α ratio for each construct assayed. Amended with permission from
American Society for Microbiology. Brown, R. C., S. Pattison, R. J. van Ree, E. Coghill,
A. Perkins, S. M. Jane, and J. M. Cunningham. 2002. Distinct domains of erythroid
Krüppel-like factor modulate chromatin remodeling and transactivation at the
endogenous beta-globin gene promoter. Mol. Cell. Biol. 22:161-170/DOI:10.1128.
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an internal domain of EKLF is sufficient to activate β-globin gene expression to wildtype levels (Brown et al., 2002). These observations are contrasted with previous studies
in which the first 104 amino acids of EKLF activated GAL4-dependent transcription
(Chen & Bieker, 1996). More importantly, our studies indicate EKLF contains separable
chromatin remodeling and transactivation domains.
PROJECT OUTLINE
I joined Dr. Cunningham’s laboratory with a strong interest in studying globin
gene regulation to understand the molecular mechanism underlying one of the most
common hematological disorders, β-thalassemia. Success in this endeavor would
identify therapeutic targets that would reverse or delay the globin gene switch, thus
ameliorating the β-thalassemic or sickle cell disease phenotype.
Based on the cellular studies by previous colleagues in the laboratory, I propose to
examine the role of the newly defined chromatin remodeling domain of EKLF
(∆221EKLF) in a whole animal model that allows the analysis of modulation of gene
expression and chromatin structure. My working hypothesis is that expression of the
chromatin remodeling domain of EKLF, in the absence of the transactivation domain, is
necessary and sufficient for altering the chromatin structure at the β-globin locus in vivo.
A corollary hypothesis is that expression of the chromatin remodeling domain alone is
not sufficient for activation of β-globin gene transcription in vivo. I plan to generate
specific mutants of the EKLF gene at the endogenous locus in a murine knock-in model
to address the following specific aims.
Specific aim 1: To characterize the cellular consequences on murine hematopoiesis of
expression of the knock-in allele in vivo.
The goal of this specific aim is to provide an initial analysis of the cellular effects
of ∆221EKLF expression in a murine model. First, matings between Δ221EKLF
heterozygous male and female animals will be established to determine if Δ221EKLF
homozygous animals are viable. If no adult Δ221EKLF homozygous animals are
observed, I will dissect embryos at different time points during gestation to determine
when and how Δ221EKLF animals die. I hypothesize that animals expressing
∆221EKLF die of a lethal anemia similar to the EKLF knock-out mice. Similarly, I
predict that cells expressing ∆221EKLF fail to execute normal terminal differentiation.
These studies should provide valuable information on the role of the chromatin
remodeling domain of EKLF in transactivation of β-globin gene transcription in vivo.
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Specific aim 2: To evaluate the functional consequences of expression of the knock-in
allele on EKLF-dependent erythroid gene transcription.
I propose to explore the effects of ∆221EKLF expression on gene transcription in
vivo. Utilizing real time RT-PCR, I will quantify the transcription of the β-globin gene
and putative non-β-globin EKLF-target genes to determine whether any of these genes
require the chromatin remodeling properties of EKLF alone for gene transcription. Based
upon our laboratory’s cellular studies, my overarching hypothesis is that expression of
the chromatin remodeling domain in the absence of the transactivation domain is not
sufficient to activate gene transcription. Together, these results will provide insights into
the role of EKLF in coordinating gene transcription at the β-globin locus and other gene
loci.
Specific aim 3: To explore the functional consequences of expression of the knock-in
allele on chromatin structure at the β-globin locus.
The studies proposed in this aim will directly test my working hypothesis that
expression of ∆221EKLF is sufficient for altering chromatin structure at the β-globin
locus. First, I will analyze the nucleosomal remodeling of the β-globin promoter as
measured by DNase I hypersensitivity. Subsequently, I will investigate the histone
acetylation and methylation patterns at the β-globin locus utilizing quantitative chromatin
immunoprecipitation (ChIP). The proposed studies should corroborate the observations
in our EKLF-dependent erythroblast model and provide insight into the role of chromatin
remodeling in transactivation of β-globin gene transcription.
In this dissertation, I describe the generation of the knock-in alleles of EKLF and
the consequences of expression of the Δ221EKLF in erythroid and megakaryocytic
differentiation. In Chapter 2, I will describe the construction of gene targeting vectors
utilizing recombineering technology and the generation of Δ221EKLF heterozygous
animals. In Chapter 3, I will report on the molecular consequences of expression of
Δ221EKLF as it relates to chromatin remodeling and transcriptional activation of βglobin. In Chapter 4, I will report on the novel role for EKLF in megakaryocytic
differentiation.
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CHAPTER 2: GENERATION OF A KNOCK-IN ALLELE OF EKLF UTLIZING
RECOMBINEERING TECHNOLOGY
INTRODUCTION
Genetically engineered mouse models have proven to be useful tools for many
applications in research, medicine, and biotechnology. The approaches to generating
these different mouse models have traditionally been based on the over-expression or
ablation of a gene using transgenic and knock-out strategies, respectively (Roebroek et al.,
2002). More recently, by using a knock-in approach and placing the expression of an
exogenous gene under the transcriptional control of cis-acting elements belonging to the
endogenous gene, investigators are able to study the gene in a more subtle manner
(Roebroek et al., 2002).
Methods used for genetic engineering have relied mostly on a conventional
approach. Restriction enzymes and DNA ligases are used to clone an appropriate piece
of DNA sequences into a targeting vector. The major limitation of this strategy is the
difficulty and time it takes to generate this vector utilizing large fragments of DNA
(Copeland et al., 2001; Liu et al., 2003). At the time that I initiated my dissertation
studies, a new and highly efficient method for manipulating the mouse genome had been
developed. Termed recombineering, this method relies on the lambda phage-based
homologous recombination in Escherichia coli to construct the targeting vector (Yu et al.,
2000; Liu et al., 2003). Using this technology, it is possible to introduce large doublestranded DNA (dsDNA) fragments into DNA cloned on plasmids, bacterial artificial
chromosomes (BACs), or P1 artificial chromosomes (PACs) via homologous
recombination without the need for restriction enzymes or DNA ligases (Copeland et al.,
2001; Liu et al., 2003). Additional advantages of using this new technology are speed,
efficiency, and reliability.
Originally, recombineering has been utilized in yeast due to its efficient DNA
double-stranded-break-and-repair recombination pathway, allowing the creation of
recombinant DNA molecules by homologous recombination (Baudin et al., 1993). These
recombination pathways allow efficient recombination of transformed linear, doublestranded DNA (dsDNA) with homologous sites in the yeast genome. Moreover,
proficient recombination occurs even with only short stretches of homologous sequence,
thereby allowing recombinant DNA to be generated in vivo without the use of restriction
enzymes and DNA ligases (Baudin et al., 1993). Unlike in yeast, dsDNA is unstable in
E. coli due to the presence of RecBCD, an ATP-dependent exonuclease that degrades
dsDNA. However, E. coli strains that lack RecBCD can be transformed by linear dsDNA
(Baudin et al., 1993).
There are disadvantages to utilizing yeast and yeast artificial chromosomes
(YACs) in recombineering. First, YACs are less stable in their yeast host, in which
recombination is potent and always active. Thus, undesired deletions and gene
rearrangements are a barrier to using this organism. In contrast, bacterial artificial
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chromosomes (BACs) are stable in E. coli (Shizuya et al., 1992; Copeland et al., 2001).
Moreover, YAC DNA is more difficult to purify compared to BAC DNA (Copeland et al.,
2001). A yeast cell may contain both wild-type and modified YACs (Peterson et al.,
1997), whereas a bacterial cell typically contains a single BAC (Copeland et al., 2001).
Finally, manipulating recombinant YACs that are generated in yeast can be laborious and
usually requires the YACs to be transferred to E. coli for subsequent manipulation,
whereas BAC modification occurs directly in E. coli (Copeland et al., 2001).
Recombineering in E. coli can be accomplished by making use of lambda phage's
homologous recombination proteins, called Red, which allow linear dsDNA fragments to
be inserted via homologous recombination into DNA cloned on plasmids (Yu et al.,
2000; Cotta-de-Almeida et al., 2003; Zhang & Huang, 2003). To generate a
recombinogenic strain of bacteria, a defective lambda prophage which lacks lysis and
replication functions but retains the Red proteins is inserted into the bacterial genome
(Yu et al., 2000). The phage genes of interest, exo, bet, and gam, are transcribed from the
λPL promoter. This promoter is repressed by the temperature-sensitive repressor cI857 at
32°C. In contrast, derepression, that is the repressor is inactive, occurs at 42°C (Yu et al.,
2000). At low temperatures (i.e., 32°C) no recombination proteins are produced.
However, following a temperature shift to 42oC for as little as 15 min, these proteins are
expressed at high levels. The 5'-3' exonuclease, exo, creates single-stranded overhangs
on introduced linear DNA; bet protects these overhangs and assists in the subsequent
recombination process. Degradation of linear DNA is protected by gam, which inhibits
the E. coli RecBCD protein (Yu et al., 2000).
Following induction of the recombination genes, linear dsDNA such as PCR
products and oligonucleotides with sufficient homology in the 5' and 3' ends to a target
DNA molecule already present in the bacteria (plasmid, BAC, or the bacterial genome
itself) can be introduced into heat-shocked and electrocompetent bacteria using
electroporation. The introduced DNA is modified by exo and bet and undergoes
homologous recombination with the target molecule. The method is so efficient that coelectroporation of a supercoiled plasmid and a linear piece of DNA into heat-shocked,
electrocompetent bacteria will work as well (Yu et al., 2000; Copeland et al., 2001; Liu
et al., 2003).
This chapter describes the generation of knock-in mutant alleles of EKLF using
the recent recombineering technology that encompasses a phage-based E. coli
homologous recombination system. Several groups have used this new form of genetic
engineering to construct standard, conditional, and knock in gene targeting vectors to
modify murine embryonic stem (ES) cells (Lui et al., 2003; Zhou et al., 2004). Utilizing
this method, I have constructed three targeting vectors in which cDNA encoding three
different truncation mutations of EKLF (Δ164EKLF, Δ221EKLF, and Δ253EKLF) have
been inserted into the endogenous murine EKLF locus. The construction of all three
targeting vectors was completed without the constraints of restriction sites and took a
shorter time than a similar strategy utilizing traditional subcloning methods.
Subsequently, the targeting vectors were used to target the endogenous murine EKLF
locus in ES cells. The animals I have generated should prove to be useful tools for
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analyzing the distinct molecular functions of EKLF in vivo.
Based upon recommendations from my graduate committee, I have chosen to
focus my dissertation studies on characterizing one strain of mice while the other two
strains are studied by my colleagues in the laboratory. I have chosen to focus on the
Δ221EKLF strain for several reasons. First, previous studies by my laboratory colleagues
have demonstrated that the Δ221EKLF domain is sufficient to alter local chromatin
structure at the endogenous β-globin promoter; however this domain alone is insufficient
to transactivate β-globin gene transcription to wild-type levels in a cellular model. Thus,
the strain of mice expressing Δ221EKLF is the most ideal model to elucidate the role of
EKLF in chromatin remodeling and gene activation in vivo.
MATERIALS AND METHODS
BAC transfer into recombinogenic strains
An EKLF BAC clone in DH10B was obtained from the BACPAC Resources
Center at Children’s Research Hospital Oakland Research Institute (CHORI). The EKLF
BAC DNA (75kb) was purified using the Miniprep DNA kit (Qiagen) as previously
described (Liu et al., 2003). Briefly, E. coli cells encoding BACs were grown overnight
in LB broth (5 mL) with chloramphenicol. Cells were collected by centrifugation at
maximum speed (12,000 x g or 13, 000 rpm) and resuspended in buffer P1 (250 µL).
Buffer P2 (250 µL) and buffer P3 (350 µL) were added to each tube, and the tubes were
spun for 4 min at 12,000 x g. The supernatant was transferred to a new 1.5 mL tube and
cleared by centrifugation for another 4 min. Isopropanol (750 µL) was added to the
mixture, and DNA was precipitated at room temperature for 10 min. The DNA was
collected by spinning the tube for 10 min at the maximal speed, washed once with 70%
ethanol (1.0 mL), air dried, and resuspended in TE (50 µL). The purified EKLF BAC
DNA (100-200 ng) was electroporated into the recombinogenic E. coli strain EL350 (a
kind gift from Dr. Neal Copeland) using a BIO-RAD electroporator at 1.75 kV, 25 µF
with the pulse controller set to 200 Ω and time constant between 4.3-4.7. Transformed
colonies were recovered on LB agar with 40 μg/mL chloramphenicol. The EKLF BAC
DNA prepared from the original DH10B and transformed EL350 bacteria was digested
with BamHI, EcoRI, and HindIII and separated on agarose gels to confirm that no DNA
rearrangements had occurred during the BAC transfer.
Plasmids
The EKLF BAC retrieval plasmid was generated by ligating PCR product AB
(left arm, EcoRI/BamHI), PCR product XY (right arm, BamHI/XbaI), and MC1-TK/polIIDT (VP101, EcoRI/XbaI) using T4 DNA ligase (Promega). The mini-targeting plasmid
was generated in two-steps. First, PCR product EF (BglII/NotI) was ligated with a floxed
Neo-containing vector, a kind gift from Dr. Neal Copeland (PL452, BamHI/NotI). Then
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PCR product CD (SalI/HindIII) and HA-∆221EKLF cDNA-containing fragment (pspHAEKLF-C3, HindIII/EcoRI) were ligated with the vector containing the Neo cassette and
PCR product EF generated in the first step. The ligation product was transformed into
chemically competent DH5α cells (Invitrogen) and plated on selective media containing
both kanamycin (50 μg/mL) and carbenicillin (100 μg/mL). Only bacterial cells
propagating the subcloned vector with the Amp and Neo resistance genes should grow
under these conditions.
PCR products were amplified using ROCHE Expand High-Fidelity PCR System
using 50 ng of BAC DNA following the manufacturer’s recommendations. PCR was
performed using an MJ Research PCR machine with the following settings: 94°C for 2
min, then 10 cycles of 94°C for 15 sec, 55°C for 30 sec, and 72°C for 45 sec. This was
followed by 15 cycles of 94°C for 15 sec, 55°C for 30 sec, 72°C for 45 sec, with an
additional 5 sec extension time each cycle. To check the PCR reaction, 5 µL of the 50 µL
PCR reaction mixture was loaded onto an agarose gel. The remaining 45 µL of PCR
product was purified using the QIAGEN PCR Purification Kit.
Recombineering
Recombineering was performed as previously described (Liu et al., 2003). To
retrieve the gap-repaired plasmid, EL350 cells containing the EKLF BAC was grown at
32oC to an OD600 = 0.5 in LB broth with chloramphenicol. The cells were transferred to
and shaken in a 42oC water bath for 15 min to induce expression of the λ recombination
proteins, and quickly chilled in ice water for 10 min. Electrocompetent cells were
prepared by washing the cells three times with ice cold water. Finally, the cell pellet was
resuspended in ice cold water (50 µL) and electroporated with the BamHI-linearized
retrieval vector (1-2 µL). After electroporation, 1 mL of LB medium was added to the
cuvette, and the culture was incubated at 32oC for 1 h with shaking. The cells were then
plated on agar plates with the appropriate antibiotic.
For targeting, frozen EL350 electrocompetent cells previously prepared in the
laboratory were used. The frozen cells were thawed at room temperature and quickly put
on ice. These cells were co-electroporated with the targeting cassette (100 ng) and the
gap-repaired plasmid (10 ng) DNA as previously described (Liu et al., 2001). The
targeting cassette was excised from the mini-targeting vector with NotI and SalI digest
and purified by the QIAGEN Gel Purification System.
Excision of the Neo cassette in bacteria
Frozen EL350 cells previously prepared in the laboratory and induced for Cre
expression by prior growth in arabinose-containing medium were used to test the excision
of the floxed Neo cassette. The EL350 strain of E. coli was previously engineered to
harbor an arabinose-inducible Cre gene (PBAD-cre) (Lee et al., 2001; Liu et al., 2003).
Plasmid DNA (10-50 ng) was electroporated into frozen electrocompetent cells (50 µL).
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LB medium (1 mL) was added to the cuvette, and the culture was shaken at 32oC for 1 h.
The cells were plated on ampicillin-containing media. DNA was extracted from selected
ampicillin-resistant colonies and digested with restriction enzymes.
Gene targeting in ES cells and generation of Δ221EKLF mice
ES cells were obtained from Specialty Media and maintained following the
manufacturer’s recommendations. For gene targeting, the NotI linearized HA∆221EKLF-KI construct was electroporated into 129Sv ES cells (Specialty Media) and
recombinants were selected in medium supplemented with G418 (Gibco) and ganciclovir
(Syntex). Selection was continued for eight days and the surviving ES clones were
picked and expanded for an additional four days. Genomic DNA was extracted from
each clone and analyzed by Southern blotting to identify properly targeted ES clones.
Sequences for 5’ and 3’ probes used in Southern blot analysis are available in Appendix
Figure A.2.
Properly targeted ES clones with a normal karyotype were injected into C57BL/6
blastocysts and transferred into pseudopregnant females to generate chimeras (Transgenic
Core Facility at St. Jude Children’s Research Hospital). Male chimeras were mated with
C57BL/6 wild-type females to generate F1 offsprings. To remove the floxed Neo
cassette, ∆221EKLF heterozygous mice were mated with mice harboring the cre
transgene diallelically expressed under the control of the adenovirus EIIa promoter that
targets expression of Cre recombinase to the early mouse embryo (Jackson Labs).
Mouse genotyping
For Southern blotting, mouse tail DNA was digested with NheI (New England
Biolabs), separated on 0.8% agarose gels, and transferred to GeneScreen Plus
hybridization transfer membrane (Perkin Elmer). A 543 bp 3' external probe was used for
hybridization. Genotyping by PCR was performed using a common WT and KI forward
primer, (5’-ATGAGGCAGAAGAGAGAGAGGAG-3’), a WT reverse primer (96 bp; 5’TGAGTGTACTGATGGAGGGTAAGA-3’), and a KI reverse primer (500 bp; 5’CCGTGTGTTTCCGGTAGTG-3’). PCR primers for genotyping were designed using
Primer Design in Clone Manager. PCR was performed on a BIORAD PCR machine with
the following settings: 94oC for 3 min followed by 32 cycles of 94oC for 30 sec, 60oC for
30 sec, and 72oC for 1 min with a final extension at 72oC for 10 min. Products were
visualized on agarose gel with ethidium bromide staining.
Husbandry of mice
The animals used in the studies were housed in the Animal Resources Center of St
Jude Children’s Research Hospital, Memphis, Tennessee, and the University of Chicago,
Chicago, Illinois, according to approved Animal Care Use Protocols (ACUP).
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Analysis of peripheral blood counts
Blood was harvested from the retro-orbital sinus into EDTA-coated
microcapillary tubes and submitted to the St Jude Children’s Research Hospital Animal
Diagnostic Laboratory for complete blood count (CBC) analysis including a peripheral
blood smear.
Primers
PCR primers for recombineering were designed using Primer Design in Clone
Manager or Primer 3. The primer sequences used for generating the HA-∆221EKLF-KI
targeting vector are:
AB-fragment (540 bp): Primer A: 5’-CGGAATTCGGTGCTGGTGGTTGTCTAGG-3’
Primer B: 5’-CGCGGATCCTGTGGTTGCTTGTAATTGA-3’;
XY-fragment (640 bp): Primer X: 5’-CGCGGATCCTACATAGCCTCTGTGCATTC-3’;
Primer Y: 5’-GCTCTAGACACCGTCTCTAGGTCAGGTA-3’; CD-fragment (596 bp):
Primer C: 5’-ACGCGTCGACCAAAGGGTCCCAAAGACCTTTC-3’; Primer D: 5’GGGTGGTGAGTGTACTGATG-3’; EF-fragment (541 bp): Primer E: 5’GGAAGATCTGGCAGGTGGTCTTGCATAGG-3’; Primer F: 5’ATAAGCGGCCGCAGTATTCAGGATGGGAGAAG-3’; Primers used to generate the
fragment containing the HA-Δ221EKLF sequence were Forward: 5’CATGCCATGGCCTATGACGTCCCAGATTACG-3’; Reverse: 5’AGTCAGGATATCCTACTTAGTCAAAGGTGGCGCTTCATGTGC-3’.
RESULTS
Generation and characterization of targeting vectors
To elucidate the role of the functional domains of EKLF in primary mouse
erythroblasts, I proposed to generate animals expressing distinct domains of EKLF
identified in previous cellular assays (Brown et al., 2002). Targeting vectors, in which
cDNA encoding HA-tagged truncation mutant of EKLF linked in cis to a Neo selection
cassette (HA-Δ221EKLF-Neo) were generated, utilizing recombineering methods. The
overall strategy is illustrated in Figure 2.1.
First, to facilitate the manipulation of the EKLF genomic locus by recombineering,
it was necessary to retrieve a region of the mouse genome containing the EKLF gene and
its cis-regulatory sequences. To accomplish this, a vector capable of retrieving an 11 kb
fragment spanning the EKLF locus was constructed by subcloning PCR amplified
fragments AB and XY into an expression vector. These regions, AB and XY, mark the 5’
and 3’ ends of the fragment to be subcloned by gap repair, respectively. Next, to obtain
the gap-repaired plasmid containing our genomic region of interest (Figure 2.2A), the
BamHI-linearized retrieval vector was electroporated into the recombinogenic bacterial
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Figure 2.1. Overview of the recombineering method used to generate vectors for
targeting in ES cell. A BAC clone containing the EKLF genomic locus was transferred
from the E. coli strain DH10B to the recombinogenic strain EL350. These cells were
electroporated with a BamHI linearized retrieval plasmid containing PCR products, AB
and XY, of homology to the EKLF BAC. By gap-repair, this plasmid rescued an 11 kb
fragment containing the EKLF gene plus 3 kb of upstream sequences and 4.5 kb of
downstream sequences. Cells containing the correct gap-repaired plasmid were
electroporated with a fragment containing HA-Δ221EKLF-floxed Neo flanked by
homology sequence from the EKLF genomic locus. This fragment was excised from the
mini-targeting vector in which PCR products CD, EF, and HA-Δ221EKLF were
subcloned into the PL452 plasmid containing a floxed Neo cassette. The resulting
plasmid containing the modified EKLF locus with insertion of HA-Δ221EKLF-floxed
NEO cassette into the ATG at amino acid 19 was linearized with NotI and electroporated
into ES cells. EKLF contains three exons (E1-E3) as denoted by black boxes. AB
(green) and XY (blue) are homologous to a region upstream and downstream of the
EKLF locus, respectively. CD (red) and EF (orange) flank the fragment to be
recombineered into the EKLF locus and are homologous to sequences in exon 1 of the
EKLF gene. The CD region, containing the ATG start site, is placed in frame with HAΔ221EKLF encoding sequences. Lox P sites are represented by black arrow heads.
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Figure 2.2. Mapping of the gap-repaired plasmid. (A) Diagram of the resultant gaprepaired plasmid obtained by electroporation of EL350 cells harboring EKLF BAC with a
BamHI-linearized retrieval vector. DT = diphtheria toxin; TK = tymidine kinase; Amp =
Ampicillin (B) To confirm the capture of the 11 kb EKLF BAC with appropriate flanking
sequences, DNA was isolated from 18 colonies and digested with XhoI (10 kb and 7 kb).
(C) Subsequently, DNA from 4 colonies (indicated by arrows from above) was digested
with NotI/SpeI (9.4 kb, 7.7 kb), XbaI (6.8kb, 6.3 kb, 4.0 kb) and HindII (7.0 kb, 6.0 kb,
4.0 kb), respectively. The expected bands are in parentheses.
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strain harboring the EKLF BAC. Since these bacterial cells had been engineered to
express the λ recombination system with induction at 42oC, homologous recombination
would occur resulting in the retrieval of the mouse genomic region flanked by the
homology arms AB and XY. DNA from 18 ampicillin-resistant colonies were purified
by the miniprep method and digested with XhoI to identify homologous recombinants.
As shown in Figure 2.2B, DNA from 17 out of 18 colonies digested with XhoI showed
the predicted 7 kb and 10 kb bands. The DNA in lane 4 appears to be undigested plasmid
containing at least two topologically different forms of DNA, corresponding to
supercoiled forms (bottom band) and nicked circles (upper band). DNA from four
colonies (indicated by arrows) was selected for further restriction enzyme analysis.
Digest with NotI/SpeI (9.4 kb / 7.7 kb), Xba1(7.0 kb / 6.0 kb / 4.0 kb), and HindIII (7.0
kb / 6.0 kb / 4.0 kb) produced fragments of the expected sizes (Figure 2.2C). Four DNA
samples confirmed by restriction mapping were sent for sequencing at the Hartwell
Center of St Jude Children’s Research Hospital. One construct had numerous mutations
and deletions near the junctions where homologous recombination took place while
another construct had base pair substitutions within the EKLF gene. The gap-repaired
plasmid with the correct sequences was selected for the next step in recombineering.
Next, a mini-targeting vector containing the knock-in fragment that will be used
to target the gap-repaired plasmid was constructed by subcloning. Fragment EF which is
homologous to the targeting site was generated by PCR, digested with BglII/NotI, and
ligated with PL452 DNA digested with NotI/BamHI. The restriction enzymes BglII and
BamHI have compatible ends (New England Biolabs). The floxed Neo gene in PL452 is
expressed from a hybrid PGK-EM7 promoter (Liu et al., 2003). Expression of Neo from
the PGK promoter permits selection of Neo resistant mammalian ES clones. On the other
hand, EM7 drives Neo expression in bacterial cells facilitating selection of Neo resistant
colonies. PCR was used to generate the CD fragment with SalI and HindIII sites and a
fragment containing HA-∆221EKLF sequences with stop codons in all three reading
frames and addition of HindIII and EcoRI restriction sites. Homology arm CD was
designed carefully so that the HA-∆221EKLF cDNA would be inserted into the
endogenous ATG start site, placing the mutant gene under the cis-regulatory control of
the endogenous locus.
To complete subcloning the mini-targeting vector (Figure 2.3A), SalI/HindIIIdigested CD fragment and HindIII/EcoRI-digested HA-∆221EKLF fragment were ligated
with SalI/EcoRI-digested PL452-EF plasmid DNA. The ligation product was
transformed into DH5α competent cells and plated on kanamycin/ampicillin selective
media. Colonies propagating the subcloned plasmid with the Amp and Neo resistant
genes should only grow under these conditions. Restriction analysis with EcoRI digest
identified six out of eighteen colonies that were homologous recombinants (Figure 2.3B,
as indicated by arrows). DNA from these six colonies was subjected to further restriction
digestion analysis with NotI/SalI (3.5 kb, 2.9 kb), NheI (5.8 kb, 0.6 kb), XhoI (3.4 kb, 3.0
kb), and HindIII/EcoRI (3.7 kb, 2.2 kb, 0.6 kb) (Figure 2.3C). Three of the six colonies
showed the correct restriction patterns. Before proceeding with the final step, the minitargeting vector was extensively analyzed by restriction enzyme digestion (Appendix
Figure A.1; Table A.2). Furthermore, sequence analysis of the junctions between CD-
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Figure 2.3. Analysis of Δ221EKLF mini-targeting vector. (A) Plasmid map of HAΔ221EKLF mini targeting vector with restriction enzyme sites. CD, EF = homologies to
EKLF gene; Amp = Ampicillin; Neo = Neomycin (B) DNA from 18 kanamycin resistant
colonies were prepared and digested with EcoRI (4.3 kb, 2.2 kb). (C) DNA from the six
correctly identified colonies (in lanes 1, 2, 3, 5, 7, and 11 panel B) was further digested
with NotI/SalI (3.5 kb, 2.9 kb), NheI (5.8 kb, 0.6 kb), XhoI (3.4 kb, 3.0 kb), and
HindIII/EcoRI (3.7 kb, 2.2 kb, 0.6 kb), respectively. The predicted fragments for the
correctly targeted vector are in parentheses
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HA-Δ221EKLF-Neo-EF confirmed that the predicted sequence was present.
Finally, to obtain the final targeting vector (Figure 2.4A) that will be used for
targeting in ES cells, the complete mini-targeting cassette was introduced into the gaprepaired plasmid by recombineering. The mini-targeting cassette containing CD-HAΔ221EKLF-Neo-EF was first excised from PL452 by NotI/SalI digest and gel-purified.
Then, the purified cassette (300 ng) was co-electroporated along with the gap-repaired
plasmid DNA (50 ng) into EL350 cells, which had been induced for Red recombination
at 42oC. Subsequently, the bacterial cells were plated on ampicillin/kanamycin selective
media. No growth was visible after 24-48 hr incubation at 32oC. Co-electroporation was
then attempted with varying amounts of targeting cassette (100-500 ng) and gap-repaired
DNA (10-100 ng). Several ampicillin/kanamycin-resistant colonies were analyzed,
however, there were no correct recombinants. I then decided to perform sequential
electroporation. First, the gap-repaired DNA was electroporated into EL350 cells. The
colonies were selected and the DNA digested with restriction enzymes to identify the
bacterial colony containing the gap-repaired plasmid. Next, the mini-targeting cassette
was electroporated into EL350 cells containing the gap-repaired plasmid. These cells had
been induced for the Red recombination genes by a short incubation at 42oC to allow
homologous recombination to occur. This resulted in modification of the EKLF genomic
locus contained in the gap-repaired plasmid by targeting the mini-cassette to the start site
of EKLF.
Prior to gene targeting in ES cells, the final targeting vector was characterized
structurally and functionally. First, to screen for aberrant gene rearrangements, DNA
from the gap-repaired plasmid (denoted 1), Δ164EKLF targeting vector (denoted 2),
Δ221EKLF targeting vector (denoted 3), and Δ253EKLF targeting vector (denoted 4)
were digested with numerous restriction enzymes. Shown in Figure 2.4A are the
restriction enzyme patterns after digestion with EcoRI, HindIII, XhoI, XbaI, AccIII, KpnI,
SpeI, and PvuI, respectively. All samples displayed the expected digestion pattern by
agarose gel electrophoresis. The predicted fragments are listed in Table 2.1. Next, to
evaluate for mutations that may have occurred during recombineering, DNA from each
targeting vector was submitted to the Hartwell Center at St Jude Children’s Research
Hospital for sequence analysis and confirmed that the targeting vectors had the correct
sequences.
Finally, to ensure that the loxP sites in the targeting vectors would properly
recombine in the presence of cre recombinase thereby removing the Neo cassette, the
targeting vectors were electroporated into EL350 cells, which had been induced for cre
expression by prior growth in arabinose-containing medium. Ampillicin-resistant
colonies were picked and the DNA from these colonies was digested with SpeI, HindIII,
BamHI, and NheI, respectively (Figure 2.4B, data shown for Δ221EKLF only). After cre
induction, there is a loss of SpeI and NheI sites resulting in only one band. Digestion
with HindIII and BamHI leads to a smaller product due to excision of the Neo
cassette as demonstrated by one of the bands being shifted lower (i.e., lower molecular
weight).
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Figure 2.4. Verification of the final targeting vector using restriction enzyme
analysis. (A) Plasmid map of the HA-Δ221EKLF final targeting vector. DNA was
prepared from ampicillin/kanamycin-resistant colonies and subjected to digestion with
various enzymes. Lane 1 = retrieval vector containing 11 kb EKLF BAC; lane 2 = HA∆164EKLF; lane 3 = HA-∆221EKLF; lane 4 = HA-∆153EKLF. (B) Plasmid maps of the
HA-Δ221EKLF final targeting vector with and without Neo. The final targeting vector
was electroporated in EL350 cells induced for cre expression and ampicillin-resistant
colonies were picked. DNA from the colonies was digested with several restriction
enzymes. CD, EF = EKLF homologies; DT = diphtheria toxin; TK = thymidine kinase;
Amp = Ampicillin; Neo = Neomycin.
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Table 2.1. Predicted fragment size with restriction enzyme digestion.
Enzyme

Retrieval (1)
plasmid

Δ164 (2)

Δ221 (3)

Δ253 (4)

EcoRI

9.5
3.4

9.6
4.0
2.1

9.5
3.8
2.1

9.4
3.7
2.1

HindIII

7.0
5.9

9.6
5.9

9.5
5.9

9.4
5.9

XhoI

7.3
5.8

7.9
5.8
1.8

7.7
5.8
1.8

7.6
5.8
1.8

XbaI

7.3
5.6

8.9
4.8
1.9

8.9
4.6
1.9

8.9
4.5
1.9

AccIII

8.0
4.9

8.0
5.5
2.0

8.0
5.4
2.0

8.0
5.3
2.0

KpnI

7.1
4.0
1.8

7.1
4.0
3.0
1.4

7.1
4.3
4.0

7.1
4.2
4.0

SpeI

12.9

12.8
2.7

12.8
2.6

12.8
2.5

PvuI

6.6
5.2
1.0

9.3
5.2
1.0

9.1
5.2
1.0

9.0
5.2
1.0

27

Targeting of the murine EKLF genomic locus
A targeting vector was generated to introduce the Δ221EKLF encoding cDNA at
the start ATG of the endogenous EKLF gene (Figure 2.5A). EKLF has only 3 exons
(Miller & Bieker, 1993). In my targeting strategy, exons 2 and 3 of the endogenous gene
were left intact. Stop codons were placed in all three reading frames to ensure proper
translation of the knock-in allele. The 5’ and 3’ homology regions were 3 kb and 4 kb,
respectively. MC1-thymidine kinase and PolII-diptheria toxin cassettes were included
for double negative selection in the ES cells. This selection strategy has been
successfully utilized in our laboratory to enrich for ES clones that have undergone
homologous recombination, as opposed to random integration (V.P. personal
communication). The data shown here are specific to HA-Δ221EKLF, however,
targeting for HA-Δ164EKLF and HA-Δ253EKLF were completed in a similar fashion.
To replace the wild-type EKLF gene with HA-Δ221EKLF in ES cells, the
targeting vector was linearized by NotI digestion and electroporated into 129/SvEv ES
cells. After eight days of selection in G418 and ganciclovir, ES cell clones were picked
and expanded. Genomic DNA from these clones was digested with EcoRV or NheI and
analyzed by Southern blot analysis with 5’ and 3’ probes, respectively. The wild-type
EKLF allele is detected as an 8.7 kb fragment with the 5’ probe and as an 11.1 kb
fragment with the 3’ probe. The recombinant allele is detected as a 9.1 kb fragment with
the 5’ probe and as a 6.8 kb fragment with the 3’ probe because of the introduction of
novel EcoRV and NheI sites into the 5’ and 3’ regions of the genes, respectively, in the
targeting vector. As shown in Figure 2.5B, ES DNA in lanes 3-7 of the top panel contain
the 8.7 kb wild-type allele and the 6.8 kb knock-in allele with the 5’ probe, whereas lanes
1-2 are wild-type ES cell DNA containing only an 8.7 kb fragment. Similarly, ES cell
DNA in lanes 3-6 of the bottom panel contain the 11.1 kb wild-type allele and the 9.1 kb
knock-in allele with the 3’ probe, and lanes 1-2 are wild-type ES cell DNA containing
only an 11.1 kb fragment. A total of 223 ES clones were screened, and 17 positive clones
were identified (~ 8% recombinants).
Δ221EKLF heterozygous mice are phenotypically normal
ES cells properly targeted with Δ221EKLF were injected into C57Bl/6 wild-type
blastocysts to generate Δ221EKLF chimeras. Male chimeras whose genetic composition
is derived from the ES cells and donor blastocysts were mated with female C57Bl/6 mice
to transmit the knock-in allele. To remove the Neo cassette, F1 offspring were then
crossed with mice harboring a cre transgene under the control of the adenovirus EIIa
promoter that targets the expression of cre recombinase to the early mouse embryo
(Jackson Laboratory). Our studies utilized mice in which the Neo cassette has been
removed, thereby eliminating the possibility of Neo gene expression interfering with our
observed results. To identify animals with the transmitted allele, tail DNA was extracted
and digested with NheI and hybridized with a 3’ probe. As shown in Figure 2.6A, DNA
from wild-type animals contains a single fragment at 11.1 kb, whereas heterozygous
animals contain two fragments, an 11.1 kb wild-type fragment and a 9.2 kb knock-in
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Figure 2.5. Targeting of cDNA encoding HA-∆221EKLF into the endogenous EKLF
locus. (A) Targeting strategy showing the wild-type EKLF locus, the targeting vector
used for gene targeting in ES cells, and the targeted locus in which HA-∆221EKLF was
inserted utilizing the endogenous ATG start site thereby placing the knock-in mutant
gene under the control of the cis-regulatory elements. Shaded rectangles indicate the
location of the external probes used for Southern blotting. N = NheI, RV = EcoRV, tk =
thymidine kinase; dt = diphtheria toxin (B) Southern blot analysis of ES clones using
EcoRV digest with 5’ probe and NheI digest and 3’ probe. The wild-type allele is
detected as an 8.7 kb and an 11.1 kb band, respectively. The knock-in allele is detected
as a 6.8 kb and 9.1 kb band, respectively.
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Figure 2.6. Identification of heterozygous mice expressing HA-∆221EKLF. (A) Top
panel: A schematic diagram of the wild-type allele and knock-in allele with and without
Neo cassette with the predicted fragment s shown. Bottom panel: Southern blot analysis
of mouse tail DNA digested with NheI and hybridized with 3’ probe. The wild-type band
is 11.1 kb; knock-in bands 9.2 kb (with Neo) and 8.1 kb (without Neo). (B) Top panel:
A diagram of the wild-type and knock-in alleles. Colored arrows indicate the location of
primers used in multiplex PCR. Dark blue = common forward primer; red = wild-type
reverse primer; purple = knock-in reverse primer. Bottom panel: A representative
photograph of agarose gel electrophoresis. PCR products amplified with DNA from
wild-type animals and heterozygous knock-in animals. The wild-type product is 96 bp
and the knock-in product is 500 bp.
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fragment. Mice in which the Neo cassette has been excised have an 8.1 kb fragment, due
to loss of a NheI site. Subsequently, a multiplex PCR method utilizing a common
forward primer with two different reverse primers was developed to facilitate genotyping
of the knock-in animals (Figure 2.6B). PCR of DNA from a wild-type animal amplified
only a 96 bp fragment with the primers, whereas DNA from a heterozygous animal
amplified a wild-type fragment of 96 bp and a knock-in fragment of 500 bp with the same
primers.
Animals heterozygous for the EKLF gene have no discernable phenotype (Nuez
et al., 1995; Perkins et al., 1995). There are, however, exceptions where deletion of a
single gene copy leads to an abnormal phenotype (Johnson et al., 1988; Muroya et al.,
2001; Deutschbauer et al., 2005) whereby the heterozygous mutation on one allele blocks
the activity of the wild-type protein is still encoded by the normal allele. To determine
whether the knock-in mutant protein encoding the Δ221EKLF domain resulted in an
unexpected phenotype, I evaluated Δ221EKLF heterozygous adult mice. First, analysis
of the Mendelian ratio from heterozygous matings demonstrated that Δ221EKLF
heterozygous animals survive to adulthood without any visible defects (Table 2.2). As
expected, these studies also revealed that Δ221EKLF homozygous animals are not viable
(see Chapter 3).
To evaluate the effects of the heterozygous knock-in allele on mouse
hematopoiesis, I examined the peripheral blood obtained from Δ221EKLF heterozygous,
EKLF-null heterozygous, and wild-type mice. Complete blood count (CBC) analysis
revealed no abnormalities in the hematological parameters measured, including white
blood cell (WBC) number, red blood cell (RBC) number, hemoglobin (Hgb), hematocrit
(Hct), and platelet (Plt) count (Table 2.3). Similarly, Wright-Giemsa staining of the
peripheral blood smear demonstrated that the circulating erythrocytes in Δ221EKLF mice
are morphologically similar to those found in wild-type and EKLF-null heterozygous
animals (Figure 2.7).
DISCUSSION
To generate the knock-in alleles of EKLF, I have utilized a lambda phage-based
recombination method called recombineering. This method relies on homologous
recombination in E. coli instead of the traditional subcloning method utilizing restriction
enzymes and DNA ligases for vector construction, thus eliminating the time and
difficulty encountered in traditional subcloning methods (Yu et al., 2000; Copeland et al.,
2001; Liu et al., 2003). The basic steps of recombineering are outlined in Figure 2.1.
The targeting vectors have been designed in such a way that the cDNA encoding the
truncation mutation of EKLF (i.e. Δ221EKLF) would be expressed under the endogenous
EKLF promoter and cis-regulatory elements. Hence, it is anticipated that the expression
of the mutant genes, ∆164EKLF, ∆221EKLF, and ∆253EKLF, would resemble that of
the wild-type endogenous EKLF protein. This approach ensures the proper expression of
the mutant factor during development and eliminates some of the obstacles in using cell
lines and artificial rescue constructs (Tsai et al., 1998). This approach has been used to
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Table 2.2. Genotyping of adult animals from heterozygous matings.
Genotype

Number of adult animalsa

WT/WT

213 / 154

Δ221EKLF/WT

402 / 307

Δ221EKLF/ Δ221EKLF

0 / 154

Totalb
a
b

615

numbers are expressed as observed / expected
total number of animals analyzed
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Table 2.3. Complete blood count analysis of Δ221EKLF heterozygous adult mice.
Parameter

WT/WT

WBC (x103/μL)
RBC (x106/μL)
Hgb (g/dL)
Hct (%)
Plt (x103/μL)

6.22 ± 1.73
9.09 ± 0.68
13.40 ± 0.70
39.60 ± 1.73
824 ± 148

WT/Δ221EKLF (p-value)
10.67 ± 2.48
8.48 ± 0.51
12.83 ± 0.23
38.30 ± 2.44
1005 ± 73.5

(0.54)
(0.49)
(0.28)
(0.25)
(0.13)

WT/EKLFnull (p-value)
11.40 ± 1.94
9.10 ± 0.34
13.43 ± 0.42
39.07 ± 1.88
1048 ± 83

(0.13)
(0.74)
(0.97)
(0.95)
(0.13)

Note: Animals were age and sex matched with 3 adult mice analyzed per cohort. Data shown are mean ± standard deviation.
Data were analyzed by the student’s t-test; p-values are listed in parentheses compared to WT.
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WT

Δ221EKLF / WT

WT / -

Figure 2.7. Normal circulating erythrocytes in Δ221EKLF heterozygous adult
animals. Peripheral blood smear (Wright-Giemsa) of adult animals obtained by retroorbital bleeds. Erythrocytes from Δ221EKLF heterozygous animals are morphologically
similar to erythrocytes from wild-type and EKLF heterozygous animals. Magnification
x100.
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demonstrate that myogenin can replace Myf5 in rib cage development (Hanks et al.,
1998) and that En-2 can replace the function of En-1 in mid-hindbrain development
(Wang et al., 1996). Similarly, knock-in mutation of GATA-3 into the GATA-1 locus
can partially replace the highly homologous factor in erythroid cell development (Tsai et
al., 1998).
Utilizing the recombineering method, I found it difficult to co-electroporate the
gap-repaired plasmid and the mini-targeting cassette as originally described (Liu et al.,
2001). Instead of co-electroporation, I electroporated the mini-targeting cassette into
electrocompetent EL350 cells which harbored the correct retrieval vector as determined
by restriction enzyme and sequence analysis. This alternative method required an
intermediate step to make the retrieval vector-containing EL350 cells electrocompetent
before electroporation with the mini -targeting cassette. In contrast, the previously
described co-electroporation method required a single step in which the retrieval vector
and mini-targeting cassette DNA were co-electroporated into previously frozen
electrocompetent EL350 bacterial cells. The time required for my altered approach was
not significant and did not greatly affect the total time required to obtain the final
targeting vectors.
Although the major step of vector construction relied on homologous
recombination in bacteria by taking advantage of the lambda phage recombination genes,
certain intermediate steps such as construction of a plasmid to retrieve an 11 kb of
sequence spanning the EKLF gene from the EKLF BAC and the mini-targeting vectors
utilized traditional subcloning methods. As a result, I encountered obstacles common to
traditional subcloning. First, I found it difficult to perform a triple ligation (fragments
AB, XY, and vector) to construct the retrieval vector. Very few colonies grew on the
selection plates, and the selected colonies did not harbor the correct plasmid. To
circumvent this problem, I increased the ratio of vector to insert in the ligation reaction
from 1:3 to 1:5 which yielded more colonies to screen. Similarly, I first tried to construct
the mini-targeting vector in a single reaction by ligating fragments CD, HA-∆221EKLF,
Neo-cassette, and EF into a pBlueScript vector. This yielded no growth on the agar
plates. An alternative method was to sequentially subclone each fragment into a vector
until a complete mini-targeting vector was constructed. To attempt this altered strategy, I
had to design new PCR primers for fragments CD and EF with different restriction sites
to facilitate subcloning. To my advantage, I used the PL450 vector which already
contained the Neo cassette to subclone in fragment EF. Next, I performed a triple
ligation using increased ratio of vector to inserts to subclone fragments CD and HAΔ221EKLF into PL450-EF. Overall, construction of the mini-targeting vectors utilizing
traditional subcloning methods proved to be the most time consuming portion of
generating the knock in alleles of EKLF. However, I was not hindered by the restriction
sites as the site for the restriction enzyme of interest was conveniently included in the
PCR amplification primers.
In my targeting strategy, I have included a Neo cassette adjacent and downstream
of the Δ221EKLF cDNA to facilitate selection during recombineering in bacteria and
targeting in ES cells. Previous studies of knock-out mice have demonstrated the
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unpredictable phenotypes that can be caused by the retention of Neo cassettes (Olson et
al., 1996; Pham et al., 1996). For example, studies in which several specific mutations
were generated within the human or murine β-globin LCR by insertion of PGK-Neo led
to abrogation of the expression of multiple globin genes downstream from the cassette.
However, deletion of the selectable marker cassette resulted in restoration of LCR
activity, suggesting that the cassette interfered with normal interactions between the LCR
and downstream regulatory elements in the gene promoters (Pham et al., 1996). To
improve Δ221EKLF expression that could be altered by an adjacent downstream Neo
transgene and to rule out any toxic effects of Neo expression at this locus, the Neo
cassette in Δ221EKLF heterozygous mice was removed by breeding to a cre transgenic
mouse line (Lasko et al., 1996). Subsequent studies in this dissertation have been
completed in mice in which the Neo cassette has been removed.
Analysis of the Δ221EKLF heterozygous animals provides an early glimpse into
the functionality of the mutant knock-in protein in vivo. Given that adult Δ221EKLF
heterozygous animals develop normally with no discernible phenotype, I speculate that
the mutant knock-in allele does not exhibit a dominant negative or haploinsufficient
phenotype. This observation is supported by my results from the CBC analysis and
peripheral blood smear which are consistent with a normal hematological phenotype.
Although the results are not significant (p-value > 0.05), it should be noted that these
studies were performed with three animals in each cohort. To minimize the possibility of
prematurely rejecting a dominant negative phenotype in Δ221EKLF animals, studies in
Δ221EKLF heterozygous animals should be repeated with a larger sample size. Indeed,
it is not uncommon for this phenotype to occur with loss-of-function studies such as been
described for the transcription factors TWIST (Johnson et al., 1988), GATA3 (Muroya et
al., 2001), and STAT6 (Bürgis & Gessner, 2007). For instance, mutant TWIST protein is
expressed and acts as a dominant negative protein by binding to target promoters and
then blocking gene transcription (Johnson et al., 1998). I will demonstrate in Chapter 3
that the mutant Δ221EKLF protein is expressed in fetal liver and possesses chromatin
remodeling function in vivo.
In summary, I have constructed knock-in targeting vectors in which cDNAs
encoding three different amino terminal truncation mutants of EKLF have been
engineered into the initiation site of the endogenous murine EKLF gene utilizing the
recombineering method. Using this method, I have constructed all three targeting vectors
in a relatively short time. Subsequently, the vectors have been used to target the
endogenous EKLF locus in ES cells via homologous recombination in order to generate
Δ221EKLF heterozygous animals. Following the recommendations of my research
committee, I have chosen to focus my dissertation studies on one strain of mice, the
∆221EKLF expressing animals. This domain of EKLF appears to be the most interesting
to study in vivo as it has been previously identified in cellular assays to possess chromatin
remodeling properties, however, lacks the ability to transactivate β-globin gene
transcription (Brown et al., 2002). This animal model will be useful to test my hypothesis
that expression of Δ221EKLF domain is sufficient to reorganize the local chromatin
architecture at the β-globin promoter but is insufficient to transcriptionally activate βglobin in vivo. In the following chapter, I will describe the functional consequences of
36

expression of Δ221EKLF mutant protein in mice homozygous for the knock-in locus.
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CHAPTER 3: CHARACTERIZATION OF THE MOLECULAR
CONSEQUENCES OF Δ221EKLF EXPRESSION IN VIVO
INTRODUCTION
The β-globin locus serves as a paradigm for studying the regulation of a
multigene locus. The murine β-globin locus, located on chromosome 7, encodes four
genes (5’-εy-βh1-βmaj-βmin-3’) which are arranged in the order of their expression during
ontogeny. Appropriate regulation of the globin genes in a tissue- and developmentalspecific manner resides in DNA elements located proximal and distal to the genes. The
β-globin locus control region (LCR) is a powerful DNA element located far upstream of
the globin genes. The LCR is required for high level expression of all the genes during
development (Grosveld et al., 1987; Bender et al., 2000). The precise mechanism of how
the LCR enhances globin gene transcription is still unsettled; however, it is thought to
involve some method of physical communication between the LCR and the globin genes
(Bulger & Groudine, 1999; Engel & Tanimoto, 2000).
The murine LCR consists of a series of DNase I hypersensitive sites (HS1-6) that
contain binding sites for transcriptional factors. A current hypothesis regards the LCR as
a holocomplex that enhances globin gene expression through recruitment of chromatin
remodeling, coactivator, and transcriptional complexes (Wijgerde et al., 1995; Bungert et
al., 1999; Tolhuis et al., 2002). Indeed, it has been shown that RNA polymerase II
(PolII) is recruited to the LCR (Johnson et al., 2003). Similarly, GATA-1, NF-E2, and
EKLF have been shown to bind the HS of the LCR (Pevny et al., 1995; Fujiwara et al.,
1996; Forsberg et al., 2000; Zhou et al., 2006). Furthermore, both GATA-1 and EKLF
are required for β-globin LCR/promoter interaction (Drissen et al., 2004; Vakoc et al.,
2005).
The β-globin promoter contains several cis-acting elements that modulate the
expression of the β-globin gene. Of these, the CACC motif is of the most interest to the
present study. Mutations of this consensus sequence lead to a thalassemic state (Orkin et
al., 1984) and specifically disrupt the binding of EKLF (Miller & Bieker, 1993; Feng et
al., 1994). Disruption of the EKLF gene by homologous recombination has
demonstrated its non-redundant role during erythroid development. EKLF-null embryos
die of a lethal anemia by embryonic day 14-15 of gestation (E14-15), as definitive
erythroid cells failed to produce β-globin transcripts in vivo (Nuez et al., 1995; Perkins et
al., 1995). Further analysis of these EKLF null embryos revealed loss of a
developmentally specific DNase I hypersensitivity site in the proximal β-globin promoter
of E14 fetal liver erythroblasts derived from EKLF null embryos (Wijgerde et al., 1996).
Because the degree of DNase I hypersensitivity of a given locus correlates with
nucleosomal remodeling (Steger & Workmann, 1996; Pazin et al., 1997), these findings
are consistent with the idea that EKLF is required for chromatin reorganization at the βglobin promoter in definitive erythroid cells.
Studies to elucidate the molecular mechanisms by which EKLF modulates
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chromatin remodeling at the β-globin promoter have relied heavily on in vitro chromatin
reconstitution assays (Armstrong et al., 1998; Kadam et al., 2000). These studies have
identified a SWI/SNF-containing multiprotein complex, E-RC1, which interacts with the
zinc finger DNA binding domain of EKLF. This interaction results in chromatin
remodeling and transcriptional activation of a chromatinized β-globin template.
Additional evidence supporting this interaction comes from studies demonstrating that
EKLF interacts with BRG1, a subunit of E-RC1 (Zhang et al., 2001). Contrary to in
vitro chromatin assays (Kadam et al., 2000), our laboratory has shown that the zinc finger
domain alone is not sufficient to remodel chromatin at the β-globin promoter in erythroid
cell lines (Brown et al., 2002). Additional sequences in the amino terminus are required
for EKLF-dependent chromatin remodeling and EKLF interaction with BRG1. However,
evidence for a direct interaction between EKLF and SWI/SNF components in vivo is still
lacking.
To test my hypothesis that expression of Δ221EKLF alone is sufficient to alter the
local chromatin structure at the β-globin locus in vivo, I will explore the consequences of
expression of Δ221EKLF and analyze the determinants required for chromatin
remodeling and β-globin transcription in vivo. Despite the advances in our understanding
of the function of EKLF as a chromatin modifier and transcriptional activator, knowledge
about the direct interaction of EKLF and SWI/SNF components and how EKLF
modulates chromatin in vivo remains elusive. Utilizing the newly generated Δ221EKLF
animals, I show that expression of Δ221EKLF results in embryonic lethality similar to
mice lacking EKLF. In stark contrast to lack of EKLF, expression of Δ221EKLF
completely restores the local chromatin structure at the β-globin promoter. However, this
domain is unable to rescue β-globin gene transcription in vivo and fails to recruit GATA1 and NF-E2 to the β-globin promoter. My results suggest that the Δ221EKLF domain is
sufficient for chromatin reorganization at the β-globin promoter, thus priming the βglobin gene for transcriptional activation. Furthermore, I show that nucleosomal
remodeling and histone modifications at the β-globin promoter are insufficient to activate
high-level β-globin transcription in vivo.
MATERIALS AND METHODS
RNA analysis
Total RNA isolated from fetal liver of E14.5 embryos was subjected to RT-PCR
analysis. RNA was extracted using the Trizol method and cDNA was prepared using the
Superscript III First Strand System (Invitrogen) following the manufacturer’s protocols.
Briefly, fetal livers from E14.5 embryos were homogenized in Trizol (200-500 µL)
reagent (Invitrogen). RNA (10 μg) was treated with Turbo DNase (2 μL)(Ambion) in a
50 µL reaction to remove genomic DNA contamination. Following DNase treatment,
DNase-treated RNA (11 µL) was used for first strand DNA synthesis.
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For RT-PCR of EKLF gene expression, cDNA (2 μL) was analyzed on a BIORAD PCR machine with the following settings: 94oC for 3 min, then 30 cycles of 94oC
for 30 sec, 60oC for 30 sec, 72oC for 1 min, followed by 72oC for 10 min. PCR products
were analyzed on agarose gels. RT-PCR primers were generated using the Primer 3
program and are as follows: Exon 1: forward: 5’ATGAGGCAGAAGAGAGAGAGGAG-3’; reverse: 5’TGAGTGTACTGATGGAGGGTAAGA -3’; Exon 2: forward: 5’CACAGTACCAAGGCCACTTC -3’; reverse: 5’-GTCCCAGGTCCAAGACAATTC-5’;
Exons 2/3: forward: 5’-GGGAAGAGCTACACCAAGAGC-3’; reverse: 5’GAAGGGACGATGTCCAGTGT-3’; HA-Δ221EKLF: forward: 5’TATGCTAGCCTCCCGGGTTA-3’; reverse: 5’-GGTCTCGGCTATCACACCTG-3’;
HPRT: forward: 5’- GCAGTACAGCCCCAAAATGG-3’; reverse: 5’AACAAAGTCTGGCCTGTATCCAA-3’ (Hodge et al., 2006).
β-globin mRNA and primary transcripts were measured by real time RT-PCR
utilizing SYBR green fluorescence on an Applied Biosystems Prism 7000 machine. The
amount of product was determined relative to a standard curve generated from a titration
of the cDNA. Dissociation curves after amplification showed that primer pairs generated
single products. The primers used for real time RT-PCR are shown in Appendix Table
A.5. Each sample was run in duplicate with at least five independent experiments
performed.
Protein analysis
Whole cell extracts were prepared from fetal liver of E14.5 embryos using the PTER reagent (Pierce) according to the manufacturer’s recommendations. Protein
concentration was measured by the Bradford Assay reagent (BioRad). One hundred
micrograms of protein was mixed with loading dye and denatured by boiling for 5 min.
The proteins were resolved on a 15% SDS-PAGE gel followed by wet transfer. The blots
were blocked in 5% milk in 0.1% PBS/Tween-20 for 1 h at room temperature with
constant rocking. Primary antibody at 1:200 dilution or 1:400 dilution for HA and EKLF,
respectively, was added and the blots were probed overnight in the cold room with
constant rocking. Blots were washed once for 15 min and twice for 5 min times with
0.1% PBS/Tween-20. Secondary antibody conjugated with horseradish peroxidase
(HRP) was added at a dilution of 1:1000 and incubated for 1 h at room temperature. The
blots were washed three times as before with 0.1% PBS/Tween-20. Peroxidase activity
was visualized by enhanced chemiluminescence (ECL) using Western blotting detection
reagents from Amersham Biosciences. The Western blots were probed with HAantibody (Santa Cruz), Cunningham laboratory generated EKLF-antibody directed
toward the zinc fingers (J.M.C unpublished), and actin-HRP (Abcam) as loading control.
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Cytospin, sections, and staining
Fetal liver erythroblasts from E14.5 embryos were made into single cell
suspension in D10 (DMEM + 10% FBS) and cytocentrifuged onto glass slides. For
immuno-localization studies, the cells were fixed in 4% formaldehyde for 20 min,
permeabilized with 0.1% Triton X-100-PBS, and blocked in 10% normal donkey serum
(Jackson ImmunoResearch) for 1 hr at room temperature. Anti-HA antibody was added
to the slides and incubated at 4°C overnight. A secondary antibody, conjugated to FITC
(Molecular Probes), was applied for another 2 h of incubation at room temperature. DNA
staining was carried out using DAPI (4', 6’diamidino-2-phenylindole) (Vector Shield).
Slides were visualized with a Leica DM IRB fluorescence microscope.
Staining with benzidine-Giemsa (Sigma) was performed according to the
manufacturer’s recommendations. Briefly, cytospin preparations were fixed in cold
methanol for 2 min, allowed to air dry, and then stained in benzidine for 20 min. After
20 min, the slides were rinsed with distilled water and placed in Giemsa stain for another
20min. Slides were rinsed with water, air dried, and mounted with cover slips.
To prepare sections of the fetal liver, wild-type, Δ221EKLF, and EKLF-null
E14.5 fetal livers were immersion fixed in 4% formalin overnight, or longer, before
submission to the Core Pathology Department at the University of Chicago. The fetal
livers were processed for sectioning and stained with H&E and Prussian blue. Slides
were viewed under a Nikon Eclipse E400 microscope fitted with a camera.
DNase I sensitivity assays
DNase I sensitivity assays were performed essentially as described by McArthur
et al. (2001) with slight modifications. Briefly, fetal livers were harvested from E14.5
mouse embryos and made into single cell suspension by passing through a 70 µm cell
strainer. Cells (6 x 106) were washed once with cold PBS and resuspended with 5 ml of
buffer A (15 mM Tris HCl (pH 7.6), 60 mM KCl, 15 mM NaCl, 1 mM EDTA, 0.5 mM
EGTA, 0.5 mM spermidine, 0.15 mM sperminine). Cells were lysed in the presence of
0.5 % (v/v) NP40, and nuclei were collected and resuspended in 1.2 mL of digestion
buffer (buffer A supplemented with 3 mM CaCl2, 75 mM NaCl). 200 µL of the nuclei
mixture was added to Eppendorf tubes containing 50 µL of the digestion mixture
containing 0-18 units of DNase I (ROCHE). Digestions were carried out at 37 °C for five
minutes before being stopped by the addition of an equal volume of stop buffer (0.1 M
NaCl, 0.1 % (w/v) SDS, 50 mM Tris-HCl (pH 8.0), 100 mM EDTA). The samples were
treated with proteinase K (500 µg/mL) at 55oC overnight and DNA recovered by
extraction with phenol/chloroform and precipitation in ethanol. The DNA was then
dialyzed against two changes of TE buffer, re-precipitated and diluted in water to a
concentration of 10 ng/µL as measured by spectrophotometry.
Real time PCR was performed on the DNA samples using SYBR green mix in a
total reaction volume of 25 µL. To quantify the amount of DNA remaining following
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DNase I treatment, a standard curve was generated from titration of undigested genomic
DNA. The values at each concentration of DNase I was normalized to a previously
determined DNase I insensitive gene, Nf-M (McArthur et al., 2001). Dissociation curves
after amplification showed that a single product was formed for each primer pair. The
primer pairs used were: βmaj promoter forward: 5’CAGGGAGAAATATGCTTGTCATCA-3’ and βmaj promoter reverse:
5’-GTGAGCAGATTGGCCCTTACC-3’; Nf-M forward: 5′GCTGGGTGATGCTTACGACC-3′ and Nf-M reverse: 5′GCGGCATTTGAACCCTCTT-3′ (McArthur et al., 2001).
Chromatin immunoprecipitation assays
ChIP assays were performed as previously described (Forsberg et al., 2000;
Kiekhaefer et al., 2002), with slight modifications. Fetal livers from E13.5 mouse
embryos were harvested and passed separately through a 70 µm cell strainer into 20 ml of
DMEM-based medium supplemented with 10% FBS. Protein-DNA cross-linking was
performed by incubating suspensions of fetal liver (at a concentration of 106 cells/mL)
with formaldehyde at a final concentration of 0.8% for 10 min at room temperature with
gentle agitation. Glycine (0.125 M) was added to quench the reaction. Cells were then
collected by centrifugation at 1000 rpm for 5 min, washed in cold PBS and a second wash
in cold PBS supplemented with Roche complete EDTA-free protease inhibitor and PMSF
(Fluka). Cross-linked cells were snap frozen and stored at -70oC until further processing.
Immunoprecipitation was performed with 1 x 107 cells per IP condition. The
buffer composition used in the ChIP assay is listed in the Appendix Table A.3. Nuclei
were isolated by incubation in cell lysis buffer for 10 min on ice followed by
centrifugation at 600 × g for 5 min. Nuclei were lysed in nuclei lysis buffer for 10 min on
ice. The lysate was sonicated for 20 minutes total using the Bioruptor sonicator
(Diagenode, Belgium) set on High power and cycles of 30 seconds ON and 30 seconds
OFF to obtain an average size of 500 bp. Soluble chromatin was diluted 1:4 with IP
dilution buffer and precleared by addition of 5 µL/mL preimmune serum followed by 50
µL of salmon sperm DNA/Protein A agarose (Millipore). An aliquot (1/10th of the total
volume) of precleared chromatin was removed (input) and used in the subsequent PCR
analysis. The remainder of the chromatin was incubated with and without primary
antibodies for 4 hours at 4oC. Immune complexes were collected by incubation with 75
µL salmon sperm DNA/Protein A agarose (Millipore) for 2 h at 4°C. A control sample
was prepared in all experiments in which IP wash buffer 1 was added instead of
chromatin. Protein A agarose pellets were washed twice with 500 µL aliquots of IP wash
buffer 1, once with IP wash buffer 2, and twice with TE buffer. Immune complexes were
eluted twice with 100 µL of IP elution buffer made fresh and NaCl (0.4 M) were added,
and cross-links were reversed by incubation overnight at 65°C. Samples were digested
with Proteinase K (0.3 mg/mL) for 2 h at 45°C. DNA was purified by Qiaquick PCR
purification kit (QIAGEN) and eluted twice with 50 µL elution buffer each time.
Immunoprecipitated DNA (2 µL) was analyzed by real-time PCR (Applied
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Biosystems Prism 7000) with the appropriate primer pairs. Samples from at least three
independent immunoprecipitations were analyzed. Product was quantified by SYBR
green fluorescence in 25 µL reactions, and the amount of product was determined relative
to a standard curve generated from a titration of input chromatin. Dissociation curves
after amplification showed that primer pairs generated single products.
Primer pairs used in ChIP analysis are listed in Appendix Table A.4. The
antibodies used in ChIP analysis were anti-HA antibody (Santa Cruz, sc-805x), antiacetylated histone H3 antibody (Upstate, 06-599), anti-RNA PolII (Santa Cruz, sc-899x),
anti-GATA-1 (Abcam, ab11963 ), and anti-NF-E2 (Santa Cruz, sc-291x ). Normal rabbit
IgG (Santa Cruz, sc-2027) was used as a control.
RESULTS
Δ221EKLF homozygous animals die in utero and exhibit ineffective erythropoiesis
Initial studies analyzing the matings of Δ221EKLF heterozygous animals
(described in Chapter 2) revealed that Δ221EKLF homozygous adult mice are not viable.
Of 615 adult mice genotyped, no live born Δ221EKLF homozygous animals were
observed. This observation is consistent with an embryonic lethal phenotype.
To determine when the animals succumb in utero, timed pregnancies were
established. These studies revealed that Δ221EKLF homozygous animals died by day
15.5 (E15.5) of gestation, a similar timepoint to EKLF-null embryos (Nuez et al., 1995;
Perkins et al., 1995) (Table 3.1). Furthermore, gross examination of the Δ221EKLF
embryos at day 15.5 of gestation revealed a pale embryo with a smaller and paler fetal
liver as compared to a wild-type littermate control (Figure 3.1). These observations are
consistent with the phenotype previously described in EKLF-null embryos of similar
chronology (Perkins et al., 1995).
The Δ221EKLF embryos appeared to lack any blood in the circulatory system,
consistent with defective erythropoiesis in vivo. This observation was supported by
benzidine-Giemsa staining of cytospun preparations of fetal liver erythroblasts and
Prussian blue staining of fetal liver sections. As shown in Figure 3.2, there are very few
benzidine-positive cells in fetal liver from Δ221EKLF embryo. To quantify the
difference, the number of benzidine-positive cells was manually counted under low
magnification. As shown in Table 3.2, similar to EKLF-null embryos, Δ221EKLF
embryos had 33% fewer benzidine-positive cells when compared to wild-type embryos.
Benzidine stains for hemoglobin (i.e. brown color), a hallmark of terminal erythroid
differentiation (Zhang et al., 2003). These observations, thus, suggest a failure of the
Δ221EKLF-expressing erythroblasts to properly accumulate hemoglobin and execute
terminal erythroid differentiation as previously demonstrated in EKLF-null cells (Drissen
et al., 2005; Pilon et al., 2008). Furthermore, the Δ221EKLF erythroblasts, like EKLFnull erythroblasts, are misshapen as evident by the irregularly shaped cell membrane
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Table 3.1. Genotyping of embryos at different stages of gestation from heterozygous
matings.
Genotype

E10.5 a

E13.5

E14.5

E15.5

Adult

WT/WT

12/12

30/27

109/89

17/29

213/154

Δ221EKLF/WT

22/23

57/55

175/179

29/27

402/307

Δ221EKLF/Δ221EKLF

13/12

22/27

73/89

4/13

0/154

47

109

357

53

615

Totalb
a
b

numbers are expressed as observed/expected
total number of animals analyzed
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Figure 3.1. Δ221EKLF embryos are anemic. (A-D) Photographs of wild-type and
Δ221EKLF embryos at E15.5. The homozygous Δ221EKLF embryo is pale and slightly
smaller compared to wild-type littermate. A marked deficit of circulating red cells is
evident. (E) Fetal liver from E15.5 wild-type and Δ221EKLF embryos. The Δ221EKLF
fetal liver is smaller and paler than fetal liver from a littermate control. (F) Photograph of
E15.5 EKLF-null embryo. The EKLF-null embryo is pale.

45

WT

Δ221

KO

Figure 3.2. Defects in cell shape and content in Δ221EKLF fetal liver erythroblasts.
Cytospin preparations of E14.5 fetal liver erythroid cells were stained with benzidineGiemsa. There are fewer benzidine-positive cells (denoted by arrowheads) from
Δ221EKLF fetal liver. Defective erythroid cell membrane is noted in Δ221EKLF.
Original magnification x 100.

Table 3.2. Quantitative analysis of benzidine-positive E14.5 fetal liver erythroblasts.
Genotype

# benzidine-positive cells/0.24mm2 field

WT

25 ± 4.2

Δ221EKLF / Δ221EKLF

8 ± 2.7

KO

7 ± 1.3

Note: Data shown as average number of benzidine-positive cells counted from three
different fields (± SD). Fetal liver from 2-3 embryos of each genotype were analyzed.
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compared to wild-type erythroblasts. This observation is consistent with the idea that
Δ221EKLF erythroblasts have membrane defects as has been described in EKLF-null
cells (Drissen et al, 2005; Hodge et al., 2006). Similarly, Prussian blue staining of fetal
liver sections revealed excess iron deposits (i.e. blue particles) in the fetal liver of
Δ221EKLF embryos (Figure 3.3, bottom panel). This observation is consistent with the
idea that Δ221EKLF expressing erythroblasts fail to properly accumulate hemoglobin
during terminal erythroid differentiation similar to that described in erythroblasts lacking
EKLF (Perkins et al., 1995; Drissen et al., 2005). Together, these observations support
the idea that Δ221EKLF mice exhibit a phenotype consistent with ineffective
erythropoiesis, comparable to EKLF-null mice (Nuez et al., 1995; Perkins et al., 1995).
∆221EKLF is expressed in fetal liver
To evaluate the expression of the mutant knock-in allele in vivo, RNA from fetal
liver erythroblasts derived from E14.5 embryos was analyzed by RT-PCR. As shown in
Figure 3.4A, the mutant transcript is detected only in RNA extracted from Δ221EKLF
fetal liver erythroblasts. Furthermore, the downstream endogenous exons 2 and 3 of
EKLF, which were left intact in the targeting strategy, are not transcribed in these mice.
This observation is expected given that a polyadenylation signal was included in the
targeting strategy to prevent interference from the endogenous downstream exons. Thus,
it appears that the mutant knock-in allele is indeed transcribed in vivo.
Because mRNA expression does not necessarily correlate with protein abundance
(Greenbaum et al., 2003), Western blotting analysis was performed to detect the
Δ221EKLF mutant protein in vivo. The ∆221EKLF encoding cDNA included a HA
epitope tag at the amino terminus to facilitate immunological detection. Using HAspecific anti-sera, the mutant protein was detected in the fetal liver (Figure 3.4B).
However, the results do not compare the level of mutant protein expression to that of
wild-type EKLF protein. Anti-EKLF antibodies are commercially available, however,
the epitopes are directed to sequences outside of the ∆221EKLF domain. Previously, our
laboratory had generated an antibody directed against the zinc finger DNA-binding
domain of EKLF (J.M.C. unpublished). Using this antibody, the mutant Δ221EKLF
protein was detected in the fetal liver of Δ221EKLF heterozygous and homozygous
embryos (Figure 3.4C) albeit at a lower level than wild-type EKLF protein. The lower
level of knock-in protein could result from instability or altered regulation of the knockin protein. However, I have shown that Δ221EKLF protein retains full chromatin
remodeling properties in a similar manner to wild-type EKLF protein (see below). More
importantly, the endogenous wild-type EKLF protein is not detected in the fetal liver of
homozygous knock-in animals. The subcellular localization of the mutant protein was
analyzed by immuno-staining. As shown in Figure 3.5 (panels j-l), the mutant protein
stained with anti-HA antibody co-localizes in the nucleus as indicated by DAPI staining.
Taken together, these results demonstrate that the mutant knock-in protein is expressed in
the fetal liver and is localized to the nucleus.
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WT

Δ221EKLF
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Δ221EKLF
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Figure 3.3. Accumulation of hemosiderin in fetal liver of mice expressing
Δ221EKLF. Paraffin-embedded sections of fetal liver from E14.5 embryos: (a-c)
hematoxylin and eosin stain and (d-f) Prussian blue stain. Hemosiderin is detected as
blue deposits in the fetal liver. Original magnification x 400.
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Figure 3.4. Expression of Δ221EKLF in fetal liver. (A) Top Panel: Schematic of the
wild-type and knock-in alleles of EKLF. Arrows indicate the primers used in RT-PCR.
Bottom Panel: Representative picture of agarose gel demonstrating that Δ221EKLF
transcripts are amplified only with RNA extracted from fetal liver of homozygous
Δ221EKLF embryos at E14.5. Additionally, downstream exons 2 and 3 of the
endogenous EKLF locus are not transcribed in these animals. HPRT transcripts are
detected as loading control. (B-C) Western blot analysis demonstrating that Δ221EKLF
knock-in protein is expressed in fetal liver. Whole cell extracts were prepared from fetal
liver of E14.5 wild-type, Δ221EKLF heterozygous, and Δ221EKLF homozygous
embryos. Whole cell extracts from J2e cell lines were included as controls. (B) An antiHA antibody was used to detect the HA-tagged mutant protein (HA-Δ221EKLF). (C)
Anti-EKLF antibody generated in our laboratory (J.M.C. unpublished) was used to detect
wild-type EKLF and mutant Δ221EKLF proteins. β-actin expression was detected as
loading controls.
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Figure 3.5. Localization of Δ221EKLF knock-in protein. Cytospin preparations of
fetal liver erythroblasts from E14.5 Δ221EKLF homozygous embryos were stained with
anti-HA antibody (j-l). The slides were mounted with VECTASHIELD® mounting
medium containing DAPI. Wild-type fetal liver erythroblasts, which lack the HA tag,
served as a negative controls (g-i) while the inducible JH31 cellular system containing a
HA-EKLF-ER fusion protein served as positive controls (a-f). In the absence of the ER
ligand, HA-EKLF-ER protein is bound to chaperone proteins in the cytoplasm but can be
translocated inside the nucleus in the presence of Tamoxifen.
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Expression of Δ212EKLF is sufficient for ß-globin promoter remodeling
To determine the functional consequences of Δ221EKLF on the chromatin
structure in vivo, nucleosomal remodeling at the β-globin promoter was determined by a
real time PCR-based DNase I hypersensitivity assay (McArthur et al., 2001). Chromatin
prepared from fetal liver nuclei was incubated with increasing amounts of the DNase I
enzyme. DNA was purified and analyzed by real time PCR. The sensitivity is plotted as
a percent of DNA remaining at different concentrations of DNase I and normalized to an
internal control region from the neurofilament Nf-M gene located on murine
chromosome 14. Nf-M is relatively resistant to DNase I digestion, although at higher
concentrations of DNase I and longer incubation time period, the DNA at this region is
digested eventually by DNase I. As shown in Figure 3.6, chromatin extracted from
Δ221EKLF fetal liver erythroblasts is sensitive to treatment with increasing amounts of
DNase I at a level comparable to chromatin from derived from wild-type erythroblasts.
In contrast, and consistent with previous observations (Wijgerde et al., 1996), chromatin
derived from EKLF-null erythroblasts are relatively insensitive to DNase I treatment up
to 18 U of enzyme. The amount of sensitivity is erythroid cell-dependent, and the fetal
liver has previously been determined to be greater than 20% hepatocytes at this stage
(McArthur et al., 2001).
Expression of Δ221EKLF induces histone modifications at the β-globin promoter
To further explore the role of Δ221EKLF in reorganizing the chromatin
architecture at the β-globin gene promoter, the acetylation and methylation patterns of
histone H3 (H3) across the β-globin locus was determined by ChIP assays. Extending
the results from the DNase I HS assay, I hypothesized that the Δ221EKLF domain is
sufficient to induce acetylation of histone H3 and methylation at K4. As shown in Figure
3.7, histones were acetylated at wild-type levels at the β-globin promoter in Δ221EKLF
erythroblasts. Interestingly, the level of acetylation was comparable to EKLF-null
erythroblasts at the 3’ coding region of the β-globin gene in Δ221EKLF erythroblasts.
This observation is consistent with the idea of a lack of significant β-globin elongation in
Δ221EKLF erythroblasts (Sawado et al., 2003). By contrast, the acetylation pattern at
the β-globin HS2 was comparable in wild-type, Δ221EKLF, and EKLF-null erythroblasts,
suggesting acetylation of HS2 of the LCR occurs independently of EKLF. Similarly,
analysis of the trimethylation pattern of lysine 4 of histone H3 revealed comparable
levels of trimethylation at the β-globin HS2; however, trimethylation at the β-globin
promoter was increased in Δ221EKLF erythroblasts to a comparable level observed in
wild-type erythroblasts (Figure 3.8). This modification, trimethylated H3K4, has been
associated with active genes in vivo (Bernstein et al., 2005). Taken together, the data
suggest that expression of the Δ221EKLF domain is sufficient for full and appropriate
chromatin remodeling activity in vivo.

52

120
wt

% DNA Remaining

100

Δ221EKLF

KO

80

* *

60

**

*
**

40
20
0
0

5

10

15

20

DNase I (Units)
Figure 3.6. DNase I sensitivity at the β-globin promoter in Δ221EKLF fetal liver
erythroblast. Plot of a quantitative real time PCR based DNase I hypersensitivity assay
used to analyze the region of murine βmaj promoter in fetal liver from E14.5 wild-type,
Δ221EKLF, and EKLF-null embryos. The results are plotted as the percent of DNA
remaining after 5 min incubation with increasing amounts of DNase I enzyme normalized
with the relatively insensitive Nf-M gene. Data shown are averages of at least three
independent experiments. Error bars indicate the standard error of the mean. Asterisks
denote p-value compared to KO. * = p-value <0.05; ** = p-value <0.001.
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Figure 3.7. Global acetylation of histone H3 across the β-globin locus. Top panel:
schematic of murine β-globin locus with location of primer pairs used in ChIP analysis
denoted by solid lines. Bottom panel: pattern of histone H3 acetylation across the βglobin locus was analyzed by ChIP assay using anti-acetylated histone H3 (AcH3)
antibody. Data shown are averages of at least five independent experiments performed in
duplicate (mean ± SEM). NS = not significant. IVR = intervening region in the β-globin
locus.
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Figure 3.8. Trimethylation pattern at lysine 4 of histone H3. The trimethylation at
lysine 4 of histone H3 (Me3H3K4) at the β-globin HS2 and promoter sequences was
analyzed by ChIP assay. Data shown are averages of at least five independent
experiments performed in duplicate (mean ± SEM). NS = not significant.
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Δ221EKLF binds to erythroid-specific gene loci
The zinc finger DNA binding domain of EKLF recognizes and binds to the
consensus sequence CCNCNCCCN found at many erythroid gene loci. To explore
whether the mutant ∆221EKLF protein was capable of binding to known EKLF
regulatory sequences in vivo, chromatin immunoprecipitation (ChIP) was performed with
a HA-specific anti-serum. In contrast to erythroid cells lacking EKLF, fetal liver
erythroblasts expressing the ∆221EKLF protein demonstrated appropriate binding of the
chromatin remodeling encoding domain to known-EKLF regulatory sequences at the βglobin locus, but not to non-erythroid gene promoters (i.e. RPII215). As shown in Figure
3.9, ∆221EKLF protein binds to the β-globin HS2, the β-globin gene promoter as well as
to the promoters of two erythroid genes, AHSP (Pilon et al., 2006) and α-globin (Shyu et
al., 2005). In contrast, the mutant protein did not bind to regions that do not contain
EKLF binding sites, including an intervening region in the β-globin locus (IVR),
downstream region of the β-globin gene, and the non-erythroid gene RPII215 (Im et al.,
2005). The RPII215 gene, located on murine chromosome 11, encodes the largest
subunit of RNA polymerase II (Pravtcheva et al., 1986). These results confirm that the
mutant protein expressed in fetal liver is capable of binding to the EKLF regulatory
sequences in vivo.
Expression of Δ221EKLF is insufficient for high-level β-globin transcription
EKLF is essential for β-globin gene transcription. Although previous cellular
studies have demonstrated that a larger domain of EKLF is required and sufficient to
activate β-globin gene transcription (Brown et al., 2002), it is not clear what determinants
are required in vivo. To determine if expression of ∆221EKLF was sufficient for
activation of gene transcription in vivo, the expression level of the adult β-globin gene in
∆221EKLF fetal liver erythroblasts from E14.5 embryos were analyzed by real time RTPCR. Similar to complete loss of EKLF, there was minimal gene expression, or
transcription as assayed by primary transcript analysis, of the β-globin gene in
∆221EKLF erythroblasts compared to wild-type erythroblasts (Figure 3.10). These
results suggest that additional amino terminal sequences are required for EKLFdependent gene activation in vivo. Moreover, the lack of β-transcripts suggests that these
animals succumbed in utero, at least in part, from a severe anemia in a similar manner to
EKLF-null animals (Nuez et al., 1995; Perkins et al., 1995).
Differential binding of factors at the β-globin LCR and promoter
The failure of Δ221EKLF to activate β-globin transcription, despite nearly normal
promoter remodeling as determined by DNase I HS formation and hyperacetylation of
histones at the β-globin promoter, led me to explore the role of Δ221EKLF in factor
recruitment to the β-globin LCR and promoter. First, occupancy of PolII at the β-globin
locus was examined by ChIP assay with anti-PolII antibody capable of detecting both
phosphorylated and unphosphorylated forms of PolII. Phosphorylation of PolII serine 5
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Figure 3.9. Differential binding of Δ221EKLF to erythroid-specific gene loci. (A)
Schematic of murine β-globin locus with location of primer pairs used in ChIP analysis
denoted by solid lines. (B) The binding of Δ221EKLF across the β-globin locus was
examined using ChIP assays with anti-HA specific anti-serum. (C) The binding of
Δ221EKLF at other erythroid-specific gene promoters (positive controls) and a nonerythroid gene promoter (negative control). Data shown are averages of at least five
independent experiments performed in duplicate (mean ± SEM). NS = not significant.
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Figure 3.10. Lack of β-globin transcripts in Δ221EKLF fetal liver erythroblasts in
vivo. RNA was extracted from fetal liver of E14.5 wild-type, Δ221EKLF, and EKLFnull embryos and treated with Turbo DNase prior to cDNA synthesis. β-globin gene
expression (as determined by mRNA levels) and transcription (as assayed by primary
transcripts) were analyzed by real time RT-PCR. Data shown are averages of at least five
independent experiments (mean ± SEM).
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is an essential step in transition from a stalled to an elongating polymerase (Phatnami
&Greenleaf, 2006). Not surprisingly, there was increased occupancy of PolII at the βglobin promoter and 3’ of the gene in wild-type erythroblasts (Figure 3.11), consistent
with active β-globin transcription. In contrast, minimal RNA polymerase II occupancy
was observed at the β-globin promoter in Δ221EKLF expressing cells of a similar
chronology. Furthermore, the amount of PolII at the 3’ region of the β-globin gene was
not significantly increased, consistent with the idea of a paused PolII complex at the βglobin promoter (Phatnami & Greenleaf, 2006). This observation is supported by the βglobin transcript data, demonstrating a significant reduction in β-globin transcripts in
Δ221EKLF erythroblasts as compared with wild-type erythroblasts (Figure 3.10). When
compared to EKLF-null cells, occupancy of PolII at the β-globin promoter was
approximately 3-fold higher in Δ221EKLF cells (p-value <0.0001). By contrast, similar
levels of PolII were recruited to HS2 of the LCR in wild-type, Δ221EKLF, and EKLFnull cells, consistent with the idea that EKLF does not mediate this step. Furthermore,
this result is not surprising given previous studies have demonstrated that recruitment of
PolII to the LCR occurs independent of recruitment to and activation of the β-globin
promoter (Johnson et al., 2003). Importantly, my results support a role for EKLF in
recruitment of PolII to the β-globin promoter, as has been previously described for
GATA-1 and NF-E2 (Johnson et al., 2001).
The β-globin promoter contains numerous binding sites for erythroid-specific and
ubiquitous transcription factors that regulate appropriate high-level expression of the βglobin gene. EKLF, GATA-1, and NF-E2 are among the best characterized
transcriptional activators and have been shown to bind the β-globin promoter sequences
and DNase HS sites (HS) at the LCR (Mahajan et al., 2007). To elucidate the role of
Δ221EKLF in EKLF-mediated transactivation of the β-globin gene, I analyzed the
recruitment GATA-1 and NF-E2 to the HS2 of the LCR and β-globin promoter in
Δ221EKLF expressing fetal liver erythroblasts (Figure 3.12). The occupancy of NF-E2
and GATA-1 at an intervening region (IVR) on the β-globin locus and the downstream
region of the β-globin gene were included as negative controls. Chromatin
immunoprecipitation analysis revealed a comparable level of NF-E2 occupancy at the βglobin HS2; however, NF-E2 occupancy at the β-globin promoter was significantly
reduced in Δ221EKLF erythroblasts as compared with wild-type erythroblasts (Figure
3.12A). These results are consistent with previous reports that demonstrate NF-E2
recruitment to HS2 of the LCR and β-globin promoter is essential for activation of βglobin transcription (Forsberg et al., 2000; Sawado et al., 2003). Similarly, GATA-1
occupancy at the β-globin HS2 was comparable in wild-type, Δ221EKLF, and EKLF-null
erythroblasts (Figure 3.12B). In contrast, GATA-1 occupancy at the β-globin promoter
was significantly reduced in Δ221EKLF as compared to wild-type erythroblasts. These
observations are consistent with the role for GATA-1 at HS2 of the LCR in co-activator
and PolII recruitment to the β-globin promoter (Cho et al., 2008). Additionally, my
results in Δ221EKLF-expressing cells suggest that a larger amino terminal domain of
EKLF is required and necessary for recruitment of GATA-1 and NF-E2 to the β-globin
promoter.
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Figure 3.11. Lack of RNA polymerase at the β-globin promoter in Δ221EKLF
expressing cells. The amount of total PolII occupancy across the β-globin locus was
examined by ChIP analysis with the polyclonal anti-PolII antibody. Data shown are
averages of at least five independent experiments performed in duplicate (mean ± SEM).
NS = not significant.
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Figure 3.12. Binding of erythroid-specific transcription factors at the β-globin
promoter in vivo. Binding of (A) NF-E2 and (B) GATA-1 across the β-globin locus was
analyzed by ChIP assay in fetal liver from E14.5 wild-type, Δ221EKLF, and EKLF-null
embryos. Data shown are averages of at least three independent experiments performed
in duplicate (mean ± SEM). NS = not significant.
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DISCUSSION
The studies in this chapter are aimed at exploring the hypothesis that expression
of Δ221EKLF alone is sufficient for altering the local chromatin structure
at the β-globin promoter in vivo. Furthermore, these studies have provided significant
insights into EKLF-mediated activation of β-globin transcription in vivo.
Expression of Δ221EKLF is not sufficient to rescue the EKLF-null phenotype
I have demonstrated in the present study that expression of Δ221EKLF in vivo
cannot rescue the EKLF null phenotype. Like mice lacking EKLF (Nuez et al., 1995;
Perkins et al., 1995), Δ221EKLF mice exhibit a phenotype consistent with ineffective
erythropoiesis and die by E15.5 of gestation. The Δ221EKLF embryo is anemic with few
hemoglobin-containing erythroblasts in the fetal liver, consistent with a block in erythroid
differentiation. Expression of Δ221EKLF protein has been confirmed in vivo. Although
the mutant Δ221EKLF protein appears to be expressed at lower levels than wild-type
EKLF protein, this alone cannot account for the observed phenotype of Δ221EKLF mice
given that the mutant protein retains full and appropriate chromatin remodeling properties
(see discussion below). Previous studies in our laboratory have shown that this domain
of EKLF cannot activate β-globin gene transcription in erythroid cell lines (Brown et al.,
2002). Thus, it was anticipated that expression of Δ221EKLF in a whole animal model
would result in embryonic lethality reminiscent of the EKLF-null mice.
Expression of Δ221EKLF is sufficient for nucleosomal remodeling and histone
modifications in vivo
Previous studies analyzing the distinct domains of EKLF in erythroid cell lines
demonstrated that chromatin remodeling and transcriptional activation functions of EKLF
are separable (Brown et al., 2002). Conclusions from these studies are that sequences
between amino acid 221-253 are necessary and sufficient for chromatin remodeling at the
β-globin promoter while additional N-terminal amino acid sequences are required for
transactivation of β-globin gene transcription. Moreover, expression of Δ221EKLF in an
erythroid cell line results in DNase I HS formation at the β-globin promoter to wild-type
levels.
My studies expand on these conclusions and provide novel results on the
chromatin remodeling property of EKLF in vivo. Indeed, DNase I hypersensitivity assays
reveal that chromatin derived from Δ221EKLF fetal liver erythroblasts is as sensitive to
DNase I treatment as wild-type chromatin, whereas chromatin from EKLF-null
erythroblasts is relatively insensitive (Figure 3.6). Because the degree of DNase I
sensitivity corresponds with nucleosomal remodeling (Steger & Workman, 1996; Pazin et
al., 1997), the data strongly suggest that expression of Δ221EKLF is sufficient for
nucleosomal remodeling at the β-globin promoter in vivo. Previous studies analyzing the
role of EKLF in chromatin remodeling have relied on in vitro chromatin reconstitution
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assays. These studies have identified a SWI/SNF-containing multiprotein complex, ERC1, which interacts with the zinc finger DNA binding domain of EKLF (Armstrong et
al., 1998; Kadam et al., 2000). This interaction results in chromatin remodeling and
transcriptional activation of a chromatinized β-globin template. Additional evidence
supporting this interaction comes from studies demonstrating that EKLF interacts with
BRG1, a subunit of E-RC1 (Zhang et al., 2001). However, evidence for a direct
interaction between EKLF and SWI/SNF components in vivo is still lacking; however,
BRG1 is a highly attractive candidate to explore.
Similarly, I show that expression of Δ221EKLF is sufficient to induce histone
modifications in vivo. First, global acetylation of histone H3 (AcH3) at the β-globin
promoter is increased in Δ221EKLF erythroblasts to an equivalent level as observed in
wild-type erythroblasts (Figure 3.7). Similarly, trimethylation at lysine 4 of histone H3 at
the β-globin promoter is increased to wild-type levels in Δ221EKLF erythroblasts (Figure
3.8). It is known that higher acetylation particularly of histones H3 and H4 are associated
with the ‘opening’ of chromatin for transcription (Yan & Boyd, 2006). Furthermore,
trimethylation at lysine 4 of histone H3 has been associated with promoters of active
genes (Bernstein et al., 2005). My results not only extend these observations to include
EKLF, but also provide evidence that the Δ221EKLF domain alone is sufficient for highlevel H3 acetylation at the β-globin promoter. EKLF has previously been shown to
interact with the histone acetyltransferase, CREB binding protein (CBP) (Zhang & Bieker,
1998; Zhang et al., 2001), which in addition to acetylation of EKLF protein can also
increase acetylation of histones (Blobel, 2002). Thus, it is highly tempting to speculate
that Δ221EKLF induces CBP recruitment and increases the acetylation of histone H3 at
the β-globin promoter in the absence of β-globin transcription.
NF-E2 and GATA-1 have been implicated in mediating H3 acetylation and
methylation at the β-globin promoter (Kiekhaefer et al., 2002; Kiekhaefer et al., 2004;
Demers et al., 2007). Using cell lines, these studies have demonstrated that GATA-1
induces H3 acetylation (Kiekhaefer et al., 2002) while NF-E2 induces H3K4
trimethylation at the β-globin promoter (Kiekhaefer et al., 2004; Demers et al., 2007). In
contrasts, my study in primary erythroblasts suggests EKLF, and more importantly the
Δ221EKLF domain, is required and sufficient for H3 acetylation and H3K4
trimethylation at the β-globin promoter in vivo. As shown in Figure 3.12, there is modest
NF-E2 and GATA-1 occupancy at the β-globin promoter in Δ221EKLF and EKLF-null
cells when compared to wild-type erythroblasts. However, in contrast to complete loss of
EKLF, expression of Δ221EKLF results in H3 acetylation and H3K4 trimethylation to a
level comparable to wild-type in Δ221EKLF erythroblasts. While it is not possible to
discount entirely the role of GATA-1 and NF-E2 in histone modifications at the β-globin
promoter, my results are consistent with the idea that Δ221EKLF is a critical mediator of
this process. It is possible the basal levels of GATA-1 and NF-E2 at the β-globin
promoter require Δ221EKLF to induce H3 acetylation and H3K4 trimethylation in vivo.

63

Nucleosomal remodeling and histone modification are not sufficient for recruitment
of erythroid-specific transcription factors to the β-globin promoter and activated βglobin transcription
In the present studies, I show that the level of β-globin transcripts in the
Δ221EKLF mice is less than 5% of wild-type mice (Figure 3.10). These results are
consistent with our previous analysis of Δ221EKLF expressed in an erythroid cell line
(Brown et al., 2002). Furthermore, the low levels of β-globin gene transcription despite
high levels of H3 acetylation and nucleosomal remodeling at the β-globin promoter is
highly reminiscent of previous studies in mice homozygous for a targeted deletion of the
LCR (Bender et al., 2000). These studies have demonstrated that deletion of the LCR
resulted in a severe reduction of β-globin transcription with concomitant decreased PolII
occupancy at the β-globin promoter (Bender et al., 2000; Sawado et al., 2003). However,
the β-globin promoter remains hyperacetylated and nuclease sensitive in LCR deletion
and wild-type mice. Taken together, these observations suggest that nucleosomal
remodeling and modification of histones are not sufficient to achieve high level β-globin
transcription in vivo, consistent with lack of LCR recruitment to the promoter.
Furthermore, the reduced level of PolII occupancy in Δ221EKLF mice is consistent with
the idea of a long range transfer of PolII from the LCR to the promoter to stimulate
transcription as has been previously described by Johnson et al. (2001).
GATA-1 and NF-E2 have both been implicated in β-globin gene activation (Kim
& Bresnick, 2007). The present studies demonstrate that EKLF is essential for
recruitment of these factors to the β-globin promoter but not HS2 of the LCR. Using
ChIP analysis, both GATA-1 and NF-E2 are recruited normally to HS2 of the LCR in
Δ221EKLF and EKLF-null erythroblasts. However, there is significantly lower GATA-1
and NF-E2 occupancy at the β-globin promoter in Δ221EKLF and EKLF-null
erythroblasts as compared to wild-type erythroblasts. My results are novel and unique to
Δ221EKLF-expressing cells, providing strong support for an essential role for EKLF in
recruitment of GATA-1 and NF-E2 to the β-globin promoter. These results are
contrasted with previous studies that have demonstrated GATA-1 and NF-E2 occupy the
β-globin promoter in erythroid cells from mice lacking the LCR (Sawado et al., 2003;
Vakoc et al., 2005), suggesting that recruitment of GATA-1 and NF-E2 to the β-globin
promoter occur independent of the LCR. The results in the present study are consistent
with two possible mechanisms of transcriptional factor recruitment to the β-globin
promoter. The first mechanism proposes that recruitment of GATA-1 and NF-E2 to the
β-globin promoter is EKLF-dependent, requiring a larger amino terminal domain of
EKLF. An alternative mechanism is that GATA-1 and NF-E2 are first recruited to the βglobin LCR (EKLF-independent) and then transferred to the β-globin promoter (EKLFdependent). Studies to examine LCR/β-globin promoter interaction would provide
additional insights into the mechanism of transcriptional factor recruitment to the βglobin promoter to stimulate gene transcription.
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A model for Δ221EKLF in β-globin promoter remodeling
Although in vitro and cellular studies have analyzed the coordinated recruitment
of transcription factors and coactivators required for high level β-globin transcription,
much knowledge remains to be gained from studying EKLF-mediated chromatin
remodeling and β-globin transcription in vivo. The results from the present studies in
Δ221EKLF mice indicate that chromatin remodeling and histone modifications are not
sufficient to achieve high-level β-globin transcription in vivo. Furthermore, these studies
suggest that Δ221EKLF is sufficient for β-globin promoter remodeling but additional
amino terminal sequences are necessary for recruitment of transcriptional factors to the
promoter. A proposed model for the role of Δ221EKLF in promoter remodeling is shown
in Figure 3.13. First, H3 acetylation and H3K4 trimethylation at HS2 of the β-globin
LCR occurs independent of EKLF. Furthermore, GATA-1, NF-E2, and PolII are
recruited normally in the absence of EKLF. In contrast, these events at the β-globin
promoter are EKLF-dependent. Similar to the observation in wild-type erythroblasts,
expression of Δ221EKLF results in an open chromatin configuration with histone
modifications consistent with an active gene promoter. However, recruitment of GATA1, NF-E2, and PolII to stimulate transcription at the β-globin promoter requires additional
amino terminal sequences of EKLF not included in the Δ221EKLF domain. In contrast,
the β-globin promoter in EKLF-null erythroblasts remains in a closed chromatin
configuration consistent with a repressed β-globin promoter. It is unclear at this juncture
what role Δ221EKLF plays in LCR/β-globin promoter interaction. Thus, further
dissection of the role of Δ221EKLF in modulation of the LCR/β-globin promoter
interaction and recruitment of other factors at the β-globin promoter will provide
additional fundamental insights into EKLF-mediated chromatin remodeling and β-globin
transcription in vivo.
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Figure 3.13. Models of β-globin promoter remodeling in erythroid cells. Histone
modifications and recruitment of GATA-1, NF-E2, and PolII to the β-globin LCR does
not require EKLF. In contrast, the events at the β-globin promoter are EKLF-dependent.
(A) In wild-type erythroblasts, EKLF induces H3 hyperacetylation and H3K4
trimethylation. Transcriptional factors (GATA-1, NF-E2, PolII) are recruited to the βglobin promoter to stimulate β-globin gene transcription. (B) In Δ221EKLF-expressing
erythroblasts, Δ221EKLF alone is sufficient to induce H3 hyeracetylation and H3K4
trimethylation. However, additional amino terminal sequences of EKLF are required for
recruitment of GATA-1, NF-E2, and PolII to stimulate β-globin gene transcription. (C)
In the absence of EKLF, the β-globin promoter remains in a closed chromatin
configuration consistent with a repressed gene promoter.
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CHAPTER 4: EXPRESSION OF Δ221EKLF RESULTS IN ALTERED
ERYTHROID MATURATION AND BLOCKED MEGAKARYOCYTIC
EXPANSION
INTRODUCTION
Hematopoiesis is a complex developmental process in which hematopoietic stem
cells (HSCs) continuously generate all blood cell lineages. The current model of
hematopoeisis proposes that HSCs proceed through multiple steps of committed
progenitors to give rise to mature blood cells in each lineage (Weissman et al., 2001,
Orkin & Zon, 2008) (see Figure1.1 in Chapter 1). This model is based historically on the
results from in vitro assays developed to quantify multi-potential progenitors and lineagerestricted progenitors of bone marrow cells cultured in semi-solid media (Nakorn et al.,
2003). Erythroid and megakaryocytic lineages are believed to be derived, at least in part,
from a common bipotential progenitor. Termed the megakaryoctye-erythrocyte
progenitor (MEP) this cell generates unipotential erythroid or megakaryocytic
progenitors (Debili et al., 1996; Nakorn et al., 2003). These precursors express many
hematopoietic transcription factors that are essential for both erythropoiesis and
megakaryopoiesis. Although many of these factors are essential, the precise mechanism
of action/pathways directing the fate of the MEP towards one lineage over another
remains obscure.
Two factors, EKLF and Fli-1, have emerged in recent studies as key players in the
erythroid-megakaryocytic differentiation switch. Both are expressed in the bipotential
MEP (Frontelo et al., 2007); however, the levels of these genes are differentially
expressed depending on the commitment fate of the MEP. During early MEP
differentiation, EKLF and Fli-1 have contrasting levels of expression. In erythroid
progenitors, EKLF expression is high, whereas in megakaryocytic progenitors Fli-1
expression is more than 60-fold greater compared with erythroid progenitors (Frontelo et
al., 2007).
EKLF and Fli-1 protein-protein interactions have also been noted (Starck et al.,
2003). These in vitro studies suggest that EKLF and Fli-1 do not inhibit each other’s
binding activity and Fli-1 mediated activation of a megakaryocytic gene promoter
construct (i.e., GpIX) can be repressed by EKLF zinc finger domain alone (Starck et al.,
2003). Supporting these observations, Bouilloux et al. (2008) have shown that knockdown of EKLF by shRNA results in an increase in megakaryocytic gene expression in
differentiated MEL cells. Furthermore, ChIP analysis revealed increased acetylation of
histone H3 and occupancy of PolII, GATA-1, and Fli-1 at megakaryocytic gene
promoters with EKLF knock-down in MEL cells. By contrast, studies by Siatecka et al.
(2007) propose that sumoylation of lysine 74 of EKLF is critical for repression of
megakaryopoiesis. Taken together, these studies suggest three potential, and nonexclusive, models of EKLF-mediated repression of megakaryopoiesis (Figure 4.1): (i)
EKLF inhibits Fli-1 gene transcription; (ii) EKLF inhibits Fli-1 binding to its target
promoters (i.e. GpIX) by protein-protein interaction; and (iii) EKLF binds to Fli-1-
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Figure 4.1. Potential models of EKLF-mediated repression of megakaryopoiesis. Shown here is a simplified diagram
depicting three possible mechanisms for EKLF-mediated repression of megakaryopoiesis with support for each model from the
current literature. (1) EKLF inhibits Fli-1 gene transcription. (2) EKLF inhibits Fli-1 binding to its targets (i.e. GpIX) by
protein-protein interaction. (3) EKLF binds to Fli-1-targeted regulatory sequences and blocks Fli-1-medication activation.
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targeted regulatory sequences and blocks Fli-1 mediated activation.
While previous studies have provided significant insights into the role of EKLF in
the erythroid-megakaryocytic differentiation program, it is important to note that these
studies have been performed in cell lines and may not recapitulate events in vivo. The
studies in this chapter seek to expand our current knowledge on the role of EKLF in MEP
differentiation utilizing the newly generated mice expressing Δ221EKLF. I report here
that, similar to complete loss of EKLF, expression of Δ221EKLF results in a block of
terminal erythroid differentiation at the proerythroblast stage, due in part, to decreased
expression of genes essential for erythroid development. However, proliferation of
erythroid progenitors is unaltered when compared to wild-type erythroblasts.
In contrast, expression of Δ221EKLF inhibits the expansion of megakaryocytic
progenitors observed with complete loss of EKLF. Molecular analysis of the Fli-1
promoter is consistent with the idea that inhibition of megakaryocytic expansion is
achieved, in part, by Δ221EKLF repression of Fli-1 through recruitment of a Sin3Acontaining repressor complex. Taken together, my results suggest that the Δ221EKLF
domain alone is sufficient for EKLF-dependent inhibition of megakaryocytic
differentiation in vivo.
MATERIALS AND METHODS
Mice
EKLF-null mice were previously generated via gene targeting by Perkins et al.
(1995). Δ221EKLF mice were generated via gene targeting as described in Chapter 2 of
this dissertation. Genotyping of wild-type, EKLF-null, Δ221EKLF embryos were
performed by PCR method as described in Chapter 3.
Colony-forming assays
Fetal livers cells were obtained by passing E14.5 fetal liver through a 70 µm cell
strainer in D10 (DMEM + 10% FBS). To evaluate the erythroid colonies (burst forming
units- erythroid; BFU-E), granulopoietic colonies (colony forming units-granulocytemacrophage; CFU-GM), and colonies containing multiple lineages of cells (colonyforming unit-granulocyte-erythroid-monocyte-megakaryocyte; CFU-GEMM), fetal liver
cell suspensions were plated (1 x 104 cells/mL) on methylcellulose medium (MethoCult
3434; StemCell Technologies) supplemented with stem cell factor, IL-3, IL-6, and
erythropoietin as recommended by the manufacturer. Cells were plated in 35mm dishes
and maintained at 37°C in a humidified atmosphere at 5% CO2 for 10–12 days. The
colonies were then counted under an inverted microscope and expressed as average
number of CFU colonies per culture. Colonies were identified as described in the
technical manual for Mouse Colony-Forming Assay using Methocult
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(http://www.stemcell.com/technical/28405_methocult%20M.pdf).
To evaluate the colony forming units-megakaryocytes (CFU-Mk), fetal liver cell
suspensions were plated (1 x105 cells/mL) on collagen medium (Megacult-C, StemCell
Technologies) containing collagen (1.1 mg/mL), recombinant thrombopoietin (50 ng/Ml),
recombinant IL-3 (10 ng/mL), recombinant IL-6 (20 ng/mL), and recombinant IL-11 (50
ng/mL). Cells were plated in double chamber slides in a 100 mm petri dish and
maintained at 37°C in a humidified atmosphere at 5% CO2 for 14 days as recommended
by the manufacturer (StemCell Technologies). The slides were fixed with methanolacetone solution after removing the double chamber and stored at -20°C until staining
could be performed. Histochemical staining was performed with acetylthiocholiniode
(Sigma). The colonies were then counted under an inverted microscope and expressed as
average number of CFU-Mk colonies per culture. CFU-Mk colonies were identified as a
group of 3 to 50 megakaryocytes per colony with acetyl cholinesterase activity, evident
by brown granules in the cytoplasm. Each experiment was performed a minimum of four
times, and the data were analyzed using a Student t-test.
FACS analysis
Fetal livers from E14.5 embryos were passed through a 23-gauge needle three
times, filtered through a 70 μM cell strainer, washed with D10 medium (DMEM + 10%
FBS), and submitted on ice to the Flow Cytometry and Cell Sorting Shared Resource
Center at St Jude Children’s Research Hospital. Cells were washed in PBS + 5% FBS
and incubated on ice in human gamma gobulin solution (100 mg/mL in PBS-5%) for
blocking of nonspecific staining. Cells were then washed in PBS-5% and incubated on
ice for 30 min with 0.5 μg of phycoerythrin (PE)-conjugated anti-mouse CD71 and
allophycocyanin (APC)-conjugated anti-mouse TER119 antibodies (BD PharMingen).
Results were analyzed using Flow-Jo software (Tree Star).
Globin gene expression by real time RT-PCR
Real time RT-PCR to analyze the expression of EKLF target genes were
performed as described in Chapter 3. The primers used for real time RT-PCR are shown
in Appendix Table A.5. Each sample was run in duplicate with at least five independent
experiments performed.
Chromatin immunoprecipitation assays
ChIP assay was performed as described in Chapter 3 with addition of anti-Sin3A
(Santa Cruz, sc-994x) antibody. Primers for ChIP analysis at Fli-1 promoter are:
forward: CGTGGACCCCGTCATTGTT and reverse:
GCACTGCGCACACAGGATACT (Frontelo et al., 2007). Primers for β-globin
promoter are the same as those described in Chapter 3.
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RESULTS
Expression of Δ221EKLF alters erythroid differentiation and inhibits expansion of
megakaryocytic progenitors
To assess the maturation and differentiation potential of fetal liver cells from
Δ221EKLF embryos, I used a flow cytometry assay that allows quantitative evaluation of
erythroid differentiation on the basis of expression of the erythroid-specific TER119 and
nonerythroid-specific CD71 (transferrin receptor) cell surface markers. Cells were flow
sorted, and a density plot of relative logarithmic fluorescence units for CD71-expressing
versus TER19-expressing was generated (Figure 4.2A). According to previous studies,
cells are defined by a characteristic pattern of CD71 and TER119 staining such that
CD71medTER119low cells are predominantly progenitor cells, CD71highTER119low are
early basophilic proerythroblasts, CD71highTER119high are early and late basophilic
erythroblasts, CD71medTER119high are chromatophilic and orthochromatophilic
erythroblasts, and CD71lowTER119high are late orthochromatophilic erythroblasts and
recticulocytes (Socolovsky et al., 2001; Zhang et al., 2003). Using this assay, I validated
previous studies that demonstrated TER119 was absent in EKLF-null fetal liver cells
while CD71 expression at the cell surface was normal (Figure 4.2A, top panels) (Hodge
et al., 2005), suggesting that loss of EKLF resulted in a block of erythroid maturation at
the proerythroblast stage (Pilon et al., 2008). As shown in Figure 4.2A (bottom panels), a
comparable pattern of CD71/TER119 staining was observed in fetal liver cells from
Δ221EKLF embryos of a similar chronology. Fetal liver cells from EKLF heterozygous
and Δ221EKLF heterozygous littermates demonstrated proper execution of the terminal
erythroid differentiation program. Thus, it appears that expression of the Δ221EKLF
domain alone is insufficient for execution of the terminal erythroid differentiation
program in vivo, resulting in a block at an early stage of erythroid differentiation.
A block in terminal erythroid differentiation as a consequence of Δ221EKLF
expression led me to speculate that Δ221EKLF affected the proliferation of
hematopoietic progenitors in vivo. To quantify the number of erythroid colonies, fetal
liver cells from wild-type, Δ221EKLF, and EKLF-null embryos were cultured in a
methylcellulose-based medium supplemented with cytokines to promote the growth of
BFU-E, CFU-GM, and CFU-GEMM colonies. As shown in Figure 4.2B, there was no
statistical difference in the number of BFU-e and CFU-GM colonies cultured from fetal
liver of wild-type, Δ221EKLF, and EKLF-null embryos. Analysis of the BFU-E colonies
revealed colonies of similar size (Appendix Figure A.3). These observations are in
agreement with previous studies in EKLF-null mice (Perkins et al., 1995), consistent with
the idea that expression of Δ221EKLF does not affect the proliferation of erythroid
progenitors. On the other hand, these studies revealed comparable numbers of CFUGEMM colonies in Δ221EKLF and wild-type animals. In contrast, there is an expansion
of CFU-GEMM colonies in EKLF-null animals. This observation was quite interesting
given that recent studies by Frontelo et al. (2007) and Bouilloux et al. (2008) proposed a
novel role for EKLF in megakaryopoiesis. Subsequently, I speculated whether the
Δ221EKLF domain alone is sufficient to inhibit the expansion of megakaryocytic
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Figure 4.2. Effects of Δ221EKLF expression on terminal erythroid differentiation
and proliferation of fetal liver progenitor cells. (A) Fluorescence-activated cell sorting
analysis of E14.5 fetal liver cells from wild-type, EKLF-null heterozygous and EKLFnull embryos (top panel). In a separate experiment, FACS analysis of E14.5 fetal liver
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in duplicate (mean ± SEM). NS = not significant; p-value for significant difference
shown.
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progenitors observed with complete loss of EKLF.
Δ221EKLF alters expression of non-β-globin-like erythroid-specific genes
To determine if the failure of terminal erythroid differentiation in Δ221EKLF
mice was due in part to lack of expression of non-β-globin erythroid-specific genes, I
examined the expression of genes that have been shown to be direct targets of EKLF
activation and those that are putative targets (Figure 4.3). Real time RT-PCR analysis
revealed that expression of known EKLF target genes, Epb4.9 (Hodge et al., 2005)
ankyrin and band 3 (Nilson et al., 2006), BKLF (Funnell et al., 2006), and AHSP (Pilon
et al., 2006) were significantly reduced in fetal liver erythroblasts from Δ221EKLF
embryos as compared to wild-type erythroblasts of similar chronology (Figure 4.3A).
Similarly, expression of Δ221EKLF could not rescue high level expression of genes
involved in heme biosynthesis (Figure 4.3B). Interestingly, these genes have not been
shown to be direct EKLF target genes. These results are consistent with earlier
observations at the β-globin locus (see Figure 3.10), confirming that a larger amino
terminal domain of EKLF is required for EKLF-dependent gene transcription in vivo.
A role for Δ221EKLF in megakaryopoiesis and regulation of Fli-1
While it is interesting that Δ221EKLF fails to rescue expression of other non-βglobin-like erythroid-specific genes in vivo and the local chromatin structure at these
gene promoters remains to be analyzed, I have decided to shift my focus to explore
further the novel observation that Δ221EKLF inhibits expansion of megakaryocytic
progenitors in vivo. Around the time that I made this observation in Δ221EKLF mice,
two interesting studies utilizing cell lines concluded that EKLF represses megakaryocytic
differentiation, at least in part, through Fli-1 repression (Frontelo et al., 2007; Bouilloux
et al., 2008). Extending these studies, Siatecka et al. (2007) proposed a critical role for
the sumoylation of lysine 74 in repression of megakaryopoiesis in a transgenic mouse
model. These studies are reminiscent of earlier studies in which overexpression of EKLF
transgene resulted in reduced platelet counts in adult mice (Tewari et al., 1998). While
these studies have significantly expanded our knowledge on the role of EKLF in
megakaryopoiesis, they have all been studied by overexpression of EKLF protein. Thus,
understanding EKLF repression of Fli-1 is of crucial importance, and the Δ221EKLF
mice provide a unique opportunity in which to explore this novel role for EKLF in vivo.
To confirm that the blocked expansion of CFU-GEMM, a mixed cell colony
containing granulocyte-erythrocyte-monocyte-megakaryocyte progenitors, was indeed
due to inhibition of megakaryocytic progenitors, I performed a more specific assay to
identify only CFU-MK by staining for acetylcholinesterase activity. Acetylcholinesterase
activity is a marker for murine megakaryocytes (Saleque et al., 2002) and is evident by
dark-brown to dark-red granules. As expected, expression of Δ221EKLF in vivo, resulted
in fewer megakaryocytic colonies as compared to complete loss of EKLF (Figure 4.4).
More importantly, the number of MK progenitors in Δ221EKLF fetal liver is equivalent.
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Figure 4.3. Altered pattern of erythroid-specific gene expression in Δ221EKLF fetal
liver erythroblasts. cDNA was synthesized from RNA extracted from fetal liver of
E14.5 wild-type, Δ221EKLF, and EKLF-null embryos and analyzed by real time RTPCR. (A) Expression level of genes previously shown to be direct targets of EKLFmediated activation. (B) Expression level of genes involved in the heme biosynthesis and
not known to be direct targets of EKLF-mediated activation. Data shown are averages of
at least five independent experiments performed in duplicate (mean ± SEM).
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to that found in the wild-type fetal liver, consistent with the idea that expression of
Δ221EKLF alone is sufficient to restore megakaryocytic progenitors to wild-type levels.
Similarly, the MK colonies obtained from Δ221EKLF fetal liver are similar in
appearance and size to those from wild-type fetal liver (Figure 4.4, bottom panel).
Together, these observations are consistent with the idea that expression Δ221EKLF
alone is sufficient to block the expansion of MK progenitors observed with complete loss
of EKLF
To explore the role of Δ221EKLF in regulating the Fli-1 promoter, real time RTPCR was used to determine the expression of Fli-1 in fetal liver erythroblasts derived
from wild-type, Δ221EKLF, and EKLF-null embryos (Figure 4.5). This was contrasted
with expression of β-globin in the same samples (Figure 4.5A). As shown in Figure
4.5B., there was no statistically significant difference in Fli-1 expression as measured by
real time RT-PCR. This observation did not agree with previous expression array
analysis (Frontelo et al., 2007) and my earlier findings that expansion of the MK
progenitors observed with complete loss of EKLF was inhibited by Δ221EKLF
expression (see Figure 4.2B). It is also possible that I did not observe repression of Fli-1
as expected because I had not analyzed the mRNA levels in the context of MK progenitor
cells or for other reasons (see Discussion below). To test if Fli-1 levels were
differentially expressed during early murine development, Fli-1 mRNA was determined
in erythroid cells derived from yolk sac of E9.5 embryos. Interestingly, a 2-fold decrease
in Fli-1 mRNA was noted in Δ221EKLF and wild-type yolk sac cells (Figure 4.5C) when
compared with EKLF-null cells, although the difference in expression only approached
statistical significance (p-value = 0.07).
To further explore the role of Δ221EKLF in regulation of Fli-1, chromatin
immunoprecipitation (ChIP) assay was utilized to analyze Δ221EKLF binding, PolII
occupancy, and histone H3 acetylation at the Fli-1 promoter contrasting these
observations with studies of factor occupancy at the β-globin promoter (Figure 4.6A-C).
Analysis of factor binding at the promoters revealed a distinct pattern of binding.
Δ221EKLF occupied the β-globin and Fli-1 promoters in a similar fashion (Figure 4.6A),
an observation consistent with previous data for wild-type EKLF (Zhou et al., 2006;
Frontelo et al., 2007). While binding of PolII protein at the β-globin promoter was
enriched in wild-type fetal liver erythroblasts, there was minimal PolII binding noted in
Δ221EKLF and EKLF-null erythroblasts (Figure 4.6B, left panel). By contrast, there was
a 2-fold decrease in PolII recruitment at the Fli-1 promoter in wild-type and Δ221EKLF
erythroblasts (Figure 4.6B, right panel), consistent with the idea that Fli-1 levels are
reduced in these cell types. Similarly, the β-globin promoter is acetylated to comparable
levels in wild-type and Δ221EKLF erythroblasts (Figure 4.6C, left panel). By contrast,
the Fli-1 promoter is hypoacetylated in these cell types and hyperacetylated in EKLF-null
cells (Figure 4.6C, right panel).
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Figure 4.4. Blocked expansion of megakaryocytic progenitors in Δ221EKLF mice.
Analysis of megakaryocytic colony-forming cells (CFU-MK) in E14.5 fetal liver cells
from wild-type, Δ221EKLF, and EKLF-null embryos. Top panel: frequency of CFU-MK
colonies counted per culture condition (1 x 10^5 cells plated). Cells were plated in double
chamber slides, maintained at 37°C in a humidified atmosphere at 5% CO2 for 14 days,
after which slides were fixed and stained for acetylcholinesterase activity, and CFU-MK
counted. Data shown are averages of at least three independent experiments performed in
duplicate (mean ± SEM). NS = not significant; p-value for significant difference shown.
Bottom panel: photographs of representative CFU-MK colonies from wild type,
Δ221EKLF, and EKLF-null fetal liver cells after staining. Acetylcholinesterase is
evident by the dark-brown granules.
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Figure 4.5. Differential expression of β-globin and Fli-1 gene in Δ221EKLF
expressing cells. cDNA prepared from RNA extracted from E14.5 fetal liver (FL) and
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real time RT-PCR for (A) β-globin mRNA, (B) Fli-1 mRNA in cells derived from fetal
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shown for significant difference. NS = not significant.
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Figure 4.6. Distinct regulation of β-globin and Fli-1 promoters in Δ221EKLF fetal
liver erythroblasts. ChIP assays were utilized to examine factor binding at the β-globin
and Fl-1 promoters, respectively. (A) Binding of Δ221EKLF at the β-globin and Fli-1
promoters in fetal liver erythroblasts from E13.5 Δ221EKLF embryos was detected by
anti-HA-specific antiserum. (B) Occupancy of total PolII at the β-globin and Fli-1
promoters in fetal liver erythroblasts from E13.5 wild-type, Δ221EKLF, and EKLF-null
embryos. (C) Acetylation of Histone H3 at the β-globin and Fli-1 promoters in fetal liver
erythroblasts from E13.5 wild-typeΔ221EKLF, and EKLF-null embryos. Data shown as
averages from at least five independent experiments performed in duplicate (mean ±
SEM). p-value shown for significant difference. NS = not significant.

79

A repressor complex is recruited to the Fli-1 promoter in Δ221EKLF cells
To explore the mechanism by which EKLF and Δ221EKLF might regulate Fli-1
transcription in vivo, ChIP assays were utilized to examine the recruitment Sin3A to the
Fli-1 promoter. Previous studies have shown that EKLF exhibits transcriptional
repression properties by interacting with Sin3A through its zinc finger DNA binding
domain (Chen & Bieker, 1996; Chen & Bieker, 2004). Sin3A binding at the Fli-1
promoter was increased 2-fold in fetal liver erythroblasts derived from wild-type and
Δ221EKLF embryos as compared to EKLF-null erythroblasts (Figure 4.7, right panel),
thus suggesting that the Fli-1 promoter is repressed. In contrast, no significant binding of
Sin3A was noted at the β-globin promoter (Figure 4.7, left panel), consistent with the
idea that a repressor complex has no role in regulation of the β-globin gene. In summary,
these results suggest that EKLF-mediated repression of Fli-1 is achieved in part by
recruitment of a Sin3A-containing complex and that expression of Δ221EKLF alone is
sufficient for this recruitment.
DISCUSSION
Studies in this chapter suggest that expression of Δ221EKLF alone is insufficient
to support erythroid terminal differentiation; however, this domain of EKLF is sufficient
to block expansion of megakaryocytic progenitors in vivo. This novel observation in
mice expressing Δ221EKLF confirms the importance of generating these animals as
valuable tools to elucidate the role of EKLF-mediated activation and repression at
erythroid- and megakaryocytic-specific gene loci in vivo.
Failure of erythroid differentiation in Δ221EKLF-expressing cells
EKLF was first characterized as a transcriptional activator that modulated βglobin gene expression during erythropoiesis. Subsequent studies extended the targets of
EKLF-mediated activation to include α-hemoglobin stabilizing protein (AHSP),
cytoskeleton proteins (ankyrin, Epb4.9), and transcription factors (BKLF) (Pilon et al.,
2006; Nilson et al., 2006; Funnell et al.,2007). Understandably, these are critical genes
for erythroid development and differentiation. The studies in this chapter not only
confirm that EKLF is essential for erythroid gene expression and terminal erythroid
differentiation, but also a domain of EKLF (Δ221EKLF) that is capable of chromatin
remodeling (see Chapter 3) is insufficient to fulfill this role in vivo. Indeed, expression of
Δ221EKLF in a whole animal model results in a block of terminal erythroid
differentiation similar that observed in complete loss of EKLF. However, proliferation of
erythroid progenitors is unaffected by expression of Δ221EKLF in vivo. Furthermore,
expression of Δ221EKLF fails to rescue the expression of ankyrin, band3, Epb4.9, BKLF,
AHSP, and all seven genes involved in heme biosynthesis to wild-type levels. It is worth
noting that none of the heme biosynthetic genes are known direct targets of EKLF. It
would be interesting to speculate on the chromatin structure at these gene promoters;
however, studies to examine the DNase I sensitivity at the gene promoters are ongoing in
80

Relative Binding

3

WT
Δ221EKLF
KO

NS

Sin3A
NS

2
p-value = 0.04

1

0

β-globin promoter

1

Fli-1 promoter

Figure 4.7. Recruitment of a Sin3A-containing repressor complex. ChIP analysis was
performed in fetal liver erythroblasts from E13.5 wild-type, Δ221EKLF, and EKLF-null
embryos. Occupancy of Sin3A was determined at Fli-1 promoter contrasted with
occupancy at β-globin promoter. Data shown as averages from at least three independent
experiments performed in duplicate (mean ± SEM). p-value shown for significant
difference. NS = not significant.

81

our laboratory and should provide significant insights into the role of Δ221EKLF at nonβ-globin erythroid-specific gene loci. While it is interesting that Δ221EKLF is
insufficient to rescue non-β-globin-like erythroid gene expression examined in the
present study, the question remains if there are genes that require only the chromatin
remodeling domain of EKLF for high-level expression in vivo. Gene expression profiling
studies utilizing the Δ221EKLF mice are ongoing in our laboratory to address this
hypothesis.
Δ221EKLF regulates Fli-1 gene and inhibits expansion of megakaryocytic
progenitors in vivo
The most compelling conclusion of the studies presented in this chapter is that
expression of Δ221EKLF is sufficient to repress megakaryocytic differentiation in vivo.
This result is particularly interesting given that studies in the previous chapter have
shown that Δ221EKLF mutant protein is expressed at a lower level than wild-type EKLF
protein. Despite this caveat, my studies show that Δ221EKLF protein is expressed at a
sufficient level to repress megakaryopoiesis in vivo. This conclusion is supported by
results from colony-forming assays demonstrating equivalent numbers of megakaryocytic
progenitors in fetal liver from Δ221EKLF and wild-type animals (Figure 4.4).
Furthermore, chromatin immunoprecipitation assays show that expression of Δ221EKLF
increases Δ221EKLF binding to the Fli-1 promoter and decreases PolII occupancy and
acetylation of histone H3 at the Fli-1 promoter (Figure 4.6A-C). Given these results, I
would have expected Fli-1 mRNA levels to be reduced in fetal liver erythroblasts from
E14.5 wild-type and Δ221EKLF embryos as compared to EKLF-null erythroblasts;
however, real time RT-PCR analysis showed no significant difference in Fli-1 mRNA
levels (Figure 4.5B). Expression arrays between EKLF wild-type and EKLF-null fetal
liver cells demonstrate only a 2.5-fold up-regulation of Fli-1 in the absence of EKLF
(Frontelo et al., 2007). By contrast, it is possible that the lineage fate decision has
already been determined prior to E14.5 of murine development. Thus, Fli-1 mRNA level
has been measured in cells that have already committed to the erythroid lineage in
Δ221EKLF homozygous and wild-type animals. In a similar manner, cells lacking EKLF
are driven towards the megakaryocytic lineage. As a result, the level of Fli-1 at this stage
of murine development may not play a role in the lineage fate decision. To reconcile this
discrepancy, I have also analyzed the levels of Fli-1 mRNA in cells derived from yolk sac
of E9.5 of wild-type, Δ221EKLF, and EKLF-null embryos (Figure 4.5C). During this
stage of murine development, the yolk sac is the source of all hematopoietic progenitor
cells (Palis et al., 1999; Lux et al., 2008). Moreover, hematopoietic progenitor cell types,
including erythrocyte and megakaryocyte progenitors, can be cultured from E9.5 yolk sac
cells (Rampon & Huber, 2003). Indeed, I found that Fli-1 mRNA was decreased 2-fold
in erythroid cells derived from E9.5 Δ221EKLF and wild-type yolk sac. Thus, these
results are consistent with the idea that the level of Fli-1 is important during early murine
development in order to influence lineage fate decisions.
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Δ221EKLF uniquely inhibits Fli-1 by recruitment of a Sin3A-containing corepressor
complex
Previous studies have shown that EKLF can function as a transcriptional repressor
through its zinc finger DNA binding domain, which can recruit Sin3A and HDAC1 (Chen
& Bieker, 1996; Chen & Bieker, 2004) and more recently through sumoylation of lysine
74, which can then recruit the Mi-2β component of the NuRD repressor complex
(Siatecka et al., 2007). Interestingly, in contrast to wild-type EKLF, expression of a
K74R EKLF mutant that cannot be sumoylated cannot repress megakaryopoiesis in
transgenic mice (Siatecka et al., 2007). Several new results obtained from my studies
directly challenge the latter observation. First, I show that expression of Δ221EKLF is
sufficient to repress megakaryocytic differentiation in vivo in a similar manner to wildtype EKLF (Figure 4.4). Thus, this indicates that sumoylation of lysine 74 is not required
for EKLF-mediated repression of megakaryopoiesis in vivo (Siatecka et al., 2007).
Furthermore, my studies utilized a model in which the Δ221EKLF protein is expressed
from the endogenous EKLF promoter under the control of cis regulatory elements. In
contrast, studies by Siatecka et al. (2007) were performed in a transgenic murine model
in which the mutant protein was over-expressed under the control of the PF4-gene
promoter (Siatecka et al., 2007), which may not recapitulate the events in vivo precisely.
The most obvious pitfall is that proteins expressed from heterologous promoters may not
be expressed in a tissue- and developmentally-specific manner as the endogenous protein.
My studies also found that Sin3A occupancy is increased at the Fli-1 promoter in
Δ221EKLF and wild-type erythroblasts (Figure 4.7). These observations are in contrast to
studies demonstrating that the NuRD repressor complex is involved in EKLF-mediated
repression of megakaryopoiesis (Siatecka et al., 2007). Sin3A is not part of the NuRD
complex (Downes et al., 2000). Taken together, my results provide strong support for the
Δ221EKLF domain in EKLF-mediated repression of megakaryocytic differentiation
through recruitment of a Sin3A-containing repressor complex.
Three potential models of EKLF-mediated repression of megakaryopoiesis can be
derived from review of the recent literature (see Introduction above; Figure 4.1).
Although support exists for each model, the precise mechanism by which EKLF
represses megakaryocytic differentiation remains to be fully explored. Based on my
current studies, I propose a modified model in which EKLF represses megakaryopoiesis,
at least in part, by inhibition of Fli-1 through recruitment of a Sin3A-containing repressor
complex (Figure 4.8). The Δ221EKLF domain alone is sufficient for this recruitment. At
this time, studies in our laboratory are ongoing to address the other two potential models
in the context of Δ221EKLF. We have planned experiments to explore expression of
megakaryocytic genes (i.e. GpIX) in vivo and occupancy of Δ221EKLF protein and
additional factor binding at these gene promoters. Furthermore, we propose studies to
confirm EKLF and Fli-1 interaction in vivo by purifying Δ221EKLF protein complexes.
Regardless of the exact mechanism of EKLF-mediated repression of megakaryopoiesis,
the Δ221EKLF mice have proven to be an indispensable model in which to explore this
question in vivo.
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Figure 4.8. Modified potential models of Δ221EKLF-mediated repression of megakaryopoiesis. Shown here is a
simplified diagram depicting three possible mechanisms for EKLF-mediated repression of megakaryopoiesis. Results obtained
from the current studies in my dissertation support the model in which EKLF inhibits Fli-1 gene transcription through
recruitment of a Sin3A-containing repressor complex. The Δ221EKLF domain alone is sufficient for this repression in vivo. It
is unclear at this juncture how Δ221EKLF affects the other two potential models of EKLF-mediated repression of
megakaryopoiesis. Studies are ongoing to address these questions.
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS
The studies presented in this dissertation contribute to our understanding of the
role of the zinc finger transcription factor EKLF or erythroid Krüppel-like factor in
erythroid and megakaryocytic differentiation. I have generated mice expressing an amino
truncation mutant of EKLF (Δ221EKLF). This domain of EKLF has been shown to
retain full and appropriate chromatin remodeling activity of wild-type EKLF in vivo.
However, expression of this domain is insufficient to rescue high-level β-globin gene
transcription in vivo. In contrast, expression of Δ221EKLF is sufficient to inhibit
expansion of megakaryocytic progenitors observed with a complete loss of EKLF. Thus,
the studies described in the preceding chapters provided novel and insightful knowledge
on the role of EKLF-mediated activation and repression at erythroid and megakaryocytic
gene loci.
Δ221EKLF mice are an excellent model to study separable chromatin remodeling
and ß-globin gene transcription in vivo
I have generated mice expressing a unique domain of EKLF that uncouples
chromatin remodeling and transactivation of β -globin transcription in an intact animal
model. Utilizing these animals, I have shown in Chapter 3 that expression of Δ221EKLF
cannot rescue the EKLF-null phenotype. Similar to EKLF-null mice, the Δ221EKLF
mice succumb in utero at E15.5 of gestation, partially as a result of severe anemia. This
observation is supported by low levels of β-globin transcripts in Δ221EKLF erythroblasts.
In contrast to lack of EKLF, expression of Δ221EKLF restores DNase I HS at the βglobin promoter and induces H3 acetylation at the β-globin promoter. Thus, chromatin
remodeling and activation at the β-globin promoter has been uncoupled in vivo.
Furthermore, the Δ221EKLF mice provide a unique opportunity in which to dissect the
determinants required for chromatin remodeling and histone modification from those
essential for β-globin gene transcription in vivo.
EKLF has been shown to associate with a SWI/SNF chromatin remodeling
complex. EKLF interaction with Brg1, the ATP-catalytic core of the E-RC1, results in
chromatin remodeling of a chromatinized β-globin template (Armstrong et al., 1998;
Kadam et al., 2000). Additionally, Δ221EKLF and Brg1 interaction has been confirmed
by in vitro studies in our laboratory (Brown et al., 2002). However, evidence for EKLF
interaction with Brg1 at the β-globin in vivo is still lacking. Thus, the Δ221EKLF mice
are the ideal reagents in which to explore this question in vivo. I propose to
immunoprecipitate EKLF and Brg1 in fetal liver erythroblasts to confirm this interaction
in vivo.
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What is the role of Δ221EKLF in erythroid-specific transcription factories?
Work from Fraser’s group has focused on understanding how genes migrate to
specialized compartments in the nucleus for transcription called transcription factories
(Osborne et al., 2004). These transcription factories are discrete foci containing nascent
RNA production and high concentrations of RNA PolII. Using a combination of
techniques including three-dimensional (3D) fluorescence in situ hybridization (FISH),
immunofluorescence, and chromosome conformation capture (3C) assays, their
laboratory has provided support for the existence of such discrete factories. In these
studies, they have shown that the β-globin gene is transcribed in the same factory as
AHSP, a gene that is similarly expressed in the erythroid cell. These genes are separated
by more than 50 mega bases on murine chromosome 7. Furthermore, they have shown
that genes present on different chromosomes such as the β- and α-globin genes, also colocalize in the same transcription factory but at a lower frequency than genes linked in cis
(Osborne et al., 2004).
The idea of a discrete foci dedicated to transcription is plausible given that the
number of factories visible in the nucleus is less than the numbers of expressed genes
(Obsorne et al., 2004). However, it is highly tempting to speculate on the factor(s) that
recruit the genes to the specialized factories. It would be interesting to determine if
EKLF is co-localized with erythroid-specific genes such as AHSP. Our laboratory
currently has an on-going collaboration with the Fraser group to address this key question.
Furthermore, studies should be extended to include the role of Δ221EKLF in these
transcription factories.
Is Δ221EKLF sufficient for formation of the Active Chromatin Hub (ACH)?
High-level expression of the β-globin genes requires the upstream enhancer LCR.
The precise mechanism of how the LCR functions to enhance transcription remains
unsettled; however, it is relatively agreed upon that it involves communication between
the LCR and the promoter. Indeed, establishment of the chromosome conformation
capture or 3C technique has greatly advanced our knowledge of this communication.
Using the 3C technique, the Grosveld and Fraser groups have determined that the LCR
moves in close proximity to actively transcribed genes, forming a structure called the
active chromatin hub (ACH). The ACH is a spatial configuration of the locus in which
the LCR loops toward the active β-globin genes (Tolhuis et al., 2002). Moreover, EKLF,
along with GATA-1 but not NF-E2, has been shown to be required for ACH formation
(Palstra et al., 2003; Vakoc et al., 2005; Kooren et al., 2007). Thus in the absence of
EKLF, a substructure is formed consisting of the regions outside of the locus and part of
the LCR but does not contain the genes (Palstra et al., 2003). A recent study from
Bresnick’s group has demonstrated that the chromatin remodeling factor, Brg1, is
required for loop formation between the LCR and the β-globin promoter (Kim et al.,
2009). Despite these advances in our knowledge on LCR/β-globin promoter interactions,
there are still many unanswered questions. Is chromatin remodeling mandatory for
LCR/β-promoter interaction via looping? Results from mutant BRG1 mice imply this is a
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requirement (Kim et al., 2009). If yes, I hypothesize that Δ221EKLF is sufficient to form
the ACH given this domain retains full chromatin remodeling activity. Is active gene
transcription an absolute requirement for ACH formation? If yes, I hypothesize that
Δ221EKLF would be insufficient to establish the ACH given that Δ221EKLF cannot
activate β-globin gene transcription. Whatever the results, it would be interesting to
know the determinants of EKLF required for ACH formation in vivo.
Does Δ221EKLF regulate other megakaryocytic genes in vivo?
In Chapter 4, I reported on new and interesting results demonstrating that
expression of Δ221EKLF alone is sufficient to block expansion of megakaryocytic
progenitors observed with complete loss of EKLF. This inhibition of megakaryopoiesis
occurs, at least in part, by repression of Fli-1, a key regulator of megakaryocytic
differentiation. Results from my ChIP analysis of the Fli-1 promoter suggest that
Δ221EKLF directly regulate Fli-1 expression in vivo through a mechanism involving
recruitment of a Sin3A-containing repressor complex to the Fli-1 promoter. These
observations are contrasted with previous studies in cell lines that demonstrated
sumoylation of EKLF at lysine 74 inhibits megakaryopoiesis through recruitment of a
Mi-2β-containing complex (Siatecka et al., 2007). It is of interest to note that Mi-2β is
not part of any Sin3A-containing corepressor complex (Downes et al., 2000). Thus, my
results are consistent with the idea that sumoylation of EKLF is not the only mechanism
for inhibition of megakaryopoiesis in vivo, as Δ221EKLF domain lacks the lysine 74
region.
I presented three potential, but not mutually exclusive, models by which
Δ221EKLF could inhibit megakaryocytic differentiation. Although my studies have
provided support for the model in which Δ221EKLF inhibits megakaryopoiesis by
directly repressing Fli-1 expression levels in vivo, it would be interesting to explore the
other potential models. It is possible EKLF, or Δ221EKLF, could directly regulate other
megakaryocytic genes, such as glycoprotein (GP) IX. I propose studies in which the
expression of GpIX is determined in Δ221EKLF erythroblasts compared to wild-type and
EKLF-null erythroblasts. I would expect the expression level of GpIX to be reduced in
Δ221EKLF and wild-type erythroblasts as compared to EKLF-null erythroblasts. It is
possible we may not see a significant difference in expression of GpIX in wild-type,
Δ221EKLF, and EKLF-null cells. Explanations for this observation are i) GpIX is not a
direct target of EKLF-mediated repression or ii) GpIX expressions needs to be
determined in the context of megakaryocytic progenitors only. Additionally, using ChIP
analysis, we should examine the binding of Δ221EKLF at GpIX promoter. If Δ221EKLF
regulates GpIX, we expect to see Δ221EKLF protein enrichment at the gene promoter.
These future studies would provide significant information on the role of Δ221EKLF in
the regulation of megakaryocytic genes.
Results from in vitro and cellular studies provide evidence for EKLF and Fli-1
interactions, and this protein-protein interaction may play a role in repression of
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megakaryopoiesis. However, evidence for this interaction in vivo is still lacking. It is
possible EKLF inhibits megakaryopoiesis by preventing Fli-1 protein binding to its target
genes through protein-protein interaction. Studies in MEL cell lines have shown that Fli1 occupancy at megakaryocytic gene promoters is increased with EKLF knock-down.
These studies, however, did not confirm EKLF-Fli-1 interaction as the mechanism for
this observation. A confirmatory experiment would be to immunoprecipitate Δ221EKLF
and Fli-1 proteins in vivo.
In conclusion, the results in this study provide novel and interesting insights in to
the in vivo role of the chromatin remodeling domain of EKLF in definitive hematopoietic
cells. The results are consistent with the idea that expression of a truncated Δ221EKLF
protein is sufficient to remodel the local chromatin architecture at the β-globin promoter;
however, expression of the Δ221EKLF protein alone is not sufficient to transactivate βglobin gene transcription in vivo. Furthermore, the current study supports a role for
Δ221EKLF in repression of the megakaryocytic progenitor expansion observed with
complete loss of EKLF. Future experiments should be directed at exploring the role of
Δ221EKLF in β-globin LCR/promoter interaction and transcription of erythroid- and
megakaryocytic-specific genes.
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Table A.1. Putative EKLF-dependent genes.
Gene

Gene symbol

Signal log ratio
(null/wt)

SRY-box containing gene 2

Sox2

6.1

acetyl-Coenzyme A synthetase 2

Acas2l

4.2

calcium channel, voltage-dependent

Cacna1b

4.0

benzodiazapine receptor associated protein 1

Bzrap1

2.3

inhibitor of DNA binding 4

Id4

1.7

potassium voltage-gated channel

Kcnq5

1.7

erythroid differentiation regulator 1

Erdr1

1.4

eukaryotic translation initiation factor 2

Eif2s3y

1.3

insulin-like growth factor binding protein 1

Igfbp1

1.3

talin 1

Tln1

1.3

erythropoietin receptor

Epor

-1

ankyrin repeat and BTB (POZ)

Abtb1

-1.1

eosinophil-associated, ribonuclease

Ear1

-1.1

myeloblastosis oncogene-like 2

Mybl2

-1.1

transportin 2 (importin 3, karyopherin beta 2b)

Tnpo2

-1.1

B-cell CLL/lymphoma 11A (zinc finger protein)

Bcl11a

-1.2

B-cell translocation gene 2, anti-proliferative

Btg2

-1.2

calmodulin regulated spectrin-associated protein

Camsap1l1

-1.2

cyclin-dependent kinase inhibitor 2D

Cdkn2d

-1.2

lamin A

Lmna

-1.2
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Table A.1 (continued).
Gene

Gene symbol

Signal log ratio
(null/wt)

aminolevulinic acid synthase 2, erythroid

Alas2

-1.3

biliverdin reductase B

Blvrb

-1.3

STEAP family member 3

Steap3

-1.3

synuclein, alpha

Snca

-1.5

ankyrin repeat domain 9

Ankrd9

-1.7

erythrocyte protein band 4.2

Epb4.2

-1.8

aminolevulinate, delta-, dehydratase

Epb4.2

-1.8

aminolevulinate, delta-, dehydratase

Alad

-1.9

eukaryotic elongation factor-2 kinase

Eef2k

-1.9

E2F transcription factor 2

E2f2

-2.4

erythrocyte protein band 4.1

Epb4.1

-2.4

Kruppel-like factor 1 (erythroid)

Klf1

-2.5

ankyrin 1, erythroid

Ank1

-2.6

LIM domain only 2

Lmo2

-2.5

Kruppel-like factor 3 (basic)

Klf3

-2.8

transferrin receptor

Tfr

-2.8

SRY-box containing gene 6

Sox6

-3.4

Duffy blood group

Dfy

-3.8

erythrocyte protein band 4.9

Epb4.9

-5.1

erythroid associated factor

Eraf; AHSP

-7.2
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SacII 6225
NotI 6215
EcoRI 5964

SacII 6396
NotI 6386
EcoRI 6135
XhoI 5853
DraII 5847

XhoI 5586
DraII 5580

F

loxP

XbaI 5335
Amp

loxP

XbaI 5239

BsaI 1291

Amp

6000

6000
1000

5000

6611 bps

5000

Neo

6440 bps

AflIII 2251

Δ 164EKLF

D

NheI 3909
EcoRI 3800

DraII 2654
XhoI 2663
SalI 2669

MW 1 2 3 1 2 3

D

AflIII 3538
BsaI 3480
DraII 3419
DraII 3371
NheI 3312
HindIII 3255

HindIII 3255

AgeI/
DralII

DraII 4259

Δ 221EKLF

AgeI 4052

AflIII 2251

C

loxP
SpeI 4091

HindIII/
EcoRI

AflIII

EcoRI

1 2 3 1 2 3 MW 1 2 3 1 2 3

Δ 253EKLF

AgeI 3956
NheI 3813
EcoRI 3704

DraII 2654
XhoI 2663
SalI 2669

HindIII/
SpeI

D

AflIII 2251

C
DraII 2654
XhoI 2663
SalI 2669

AflIII 3442
BsaI 3384
NheI 3312
HindIII 3255

Δ221EKLF

EcoRI/
XbaI

2000

3000

loxP

SpeI 4187

C

Δ164EKLF

NheI

6344 bps

BsaI 1291

1000

4000

DraII 4355

loxP

Af lIII 3709
BsaI 3651
DraII 3590
DraII 3542
SacII 3530
AgeI 3374
NheI 3312

23.1 kb
9.4 kb
6.6 kb

5000

Neo

3000

DraII 4526

NheI 4080
EcoRI 3971

Δ 253EKLF

2000

4000
3000

AgeI 4223

Amp

6000

BsaI 1291

Δ 221EKLF

2000

4000

SpeI 4358

loxP

1000

Δ 164EKLF
Neo

F

E

E

E

F

XbaI 5506

SacII 6129
NotI 6119
EcoRI 5868

XhoI 5682
DraII 5676

Δ253EKLF

SacIII/
SpeI

BsaI

NotI/
SalI

1 2 3 1 2 3 MW 1 2 3 1 2 3

XhoI

XbaI/
SalI

1 2 3 1 2 3

2.3 kb
2.0 kb
1.4 kb
1.1 kb
0.87 kb
06.0 kb

Figure A.1. Confirmation of the mini-targeting vectors. The top panel shows the
plasmid maps of the mini targeting vectors, HA-Δ164EKLF, HA-Δ221EKLF, and HAΔ253EKLF, respectively. The bottom panel is representative agarose gels after digestion
of the mini targeting vectors with the restriction enzymes. Lane 1 = HA-∆164EKLF; lane
2 = HA-∆221EKLF; lane 3 = HA-∆153EKLF. The predicted fragments are given in
Appendix Table A.2.
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Table A.2. Predicted fragment size with restriction enzyme digestion.
Δ164 (1)

Δ221 (2)

Δ253 (3)

NheI

5.8
0.8

5.8
0.6

5.8
0.5

AgeI/DraIII

3.2
2.6
0.9

3.8
2.6

3.7
2.6

EcoRI/XbaI

4.4
1.5
0.6

4.3
1.5
0.6

4.2
1.5
0.6

HindIII/EcoRI

3.7
2.2
0.7

3.7
2.2
0.6

3.7
2.2
0.5

AflIII

5.2
1.5

5.2
1.3

5.2
1.2

EcoRI

4.4
2.2

4.3
2.2

4.2
2.2

HindIII/SpeI

5.5
1.1

5.5
0.9

5.5
0.8

SacIII/SpeI

3.7
2.0
0.8

4.4
2.0

4.3
2.0

BsaI

4.3
2.3

4.3
2.2

4.3
2.1

NotI/SalI

3.7
2.9

3.5
2.9

3.4
2.9

XhoI

3.4
3.2

3.4
3.0

3.4
2.8

XbaI/SalI

3.8
2.8

3.8
2.7

3.8
2.6

Enzyme
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A. 5’ Southern blot probe
CTAGCTAAAGCCTTTCTTATTAATGCCAAAAGAACTGAAGCAGGAAATCA
CGGTGGTTACACAGCCCAGCACCTAAGCCCAATTTACAGGACAAGGCTCA
TTTTTATTATTAGAGCTCCTTTGGTAACAGAGAAGGCTGCTCACAGCCAGC
ATGCTCAAGGTTGTATAAAGCACAACAATGTTATTTGTCTTCAGAAAAAC
ATCTGAGGTGTGGGAACATCATTTACCCTGACTATGCT
B. 3’ Southern blot probe
AATTCGCCCTTAAGGGCCAGAACTTGGAGCGCCTTAGAAGTCACGTGACA
GCCAATGCCCAAGGGAGAGGCGTGTCCACGGATGAAGCCTATCCGGAGC
TGAGTCGGCCAGAAGCGGGAGGACGGGGCGGGGAGGACATTGGAGGAG
GCGGGGTCCGCTTGTGGGACAACTTCATAGGAAGCCCCGCCTCCGTATTG
GGCCTGGCGGGCTTCGTCTCCACCCTCGCGAAGCCGGGACACAGATCTCT
TCGGTTTTTAGGGGAAGTTCATCTGAATCTCGTGACCCGGCTGTCCCCGGG
TCTTTTAGAGTCCATTGCTGTCGCCTCATGGCAACACTGAGATCGCTGCTG
CTGGCTGCGCTGCTGTGGGTCCCTGCCGAAGCCCTGAGCTGCTATGGGGA
CTCCGGGCAGCCTGTGGATTGGTGAGTAAGTAGTCGCGGGACTGTCCCCC
GCACACTGCCTGGGGACCGGCGCGGGAATCCAAAAAACCTCAGATTCCTT
CTCTCCCCCAACCTCATGTCTTCACGGACCTCCAGGTTCGTGGT
Figure A.2. Sequences of Southern blot probes used in screening targeted ES cells
and genotyping of animals. (A) The 239 bp 5’ probe was used with EcoRV digest to
identify an 8.7 kb wt band and 6.8 kb KI band. (B) The 543 bp 3’ probe was used with
NheI digest to identify an 11.1 kb wt band and 9.1 kb KI band.
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Table A.3. Buffer composition used in ChIP analysis.
Buffer

Composition

Cell Lysis

10mM Tris pH 8.0
10mM NaCl
0.2% NP40
Add Protease inhibitors (Roche) and PMSF
before use.

Nuclei Lysis

50mM Tris pH 8.0
10mM EDTA
1% SDS
Add Protease inhibitors (Roche) and PMSF
before use.

IP Dilution Buffer

20mM Tris pH 8.0
2mM EDTA
150mM NaCl
1% Triton X-100
0.01% SDS
Add Protease inhibitors (Roche) and PMSF
before use.

IP Wash Buffer 1

20mM Tris pH 8.0
2mM EDTA
50mM NaCl
1% Triton X-100
0.1% SDS

IP Wash Buffer 2

10mM Tris pH 8.0
1mM EDTA
0.25M LiCl
1% NP40
1% Deoxycholic acid

Elution Buffer

100mM NaHCO3
1% SDS (use high quality SDS)
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Table A.4. Primers used for ChIP analysis.
Region

Primer sequence

Reference

HS2

5’-AGTCAATTCTCTACTCCCCACCCT-3’
5’-ACTGCTGTGCTCAAGCCTGAT-3’

Kiekhaefer et al., 2002

IVR

5’-GTATGCTCAATTCAAATGTACCTTATTTTAA-3’
5’-TTACCTCTTTATTTCACTTTTACACATAGCTAA-3’

Kiekhaefer et al., 2002

βmaj pro

5’-CAGGGAGAAATATGCTTGTCATCA-3’
5’-GTGAGCAGATTGGCCCTTACC-3’

Kiekhaefer et al., 2002

βmaj ex3

5’-GCCCTGGCTCACAAGTACCA-3’
5’-TTCACAGGCAAGAGCAGGAA-3’

Kiekhaefer et al., 2002

AHSP

5’-CTAACTCCAGGGAAGCCTCACC-3’
5’-TTTGTGTGTCTTCTGCACTAAGCG-3’

Pilon et al., 2006

Fli-1

5’-CGTGGACCCCGTCATTGTT-3’
5’-GCACTGCGCACACAGGATACT-3’

Frontelo et al., 2007

RPII215

5’-GCGAATCTATAAAGGGCGTCACT-3’
5’-TCGGCGCTTCTGAGGAGA-3’

Kiekhaefer et al., 2002

α-globin pro

5’-TGACCAAGGTAGGAGGATACTAACTTCT-3’
5’-TTGCCCGGACACACTTCTTAC-3’

Anquita et al., 2004
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Table A.5. Primers used for real time RT-PCR analysis.
Gene

Primer sequence

Reference

Alas 2

5’-CACCTATGCTTAAGGAGCCA-3’
5’-CAGAAGCACACAGGAAAGCA-3’

Drissen et al., 2005

Alad

5’-CTTTGATCTCAGGACTGCTG-3’
5’-AACAGCTGCGGTGCAAAGTA-3’

Drissen et al., 2005

Pbgd

5’-TACTTCTGGCTTCCAAGTGC-3’
5’-CAAGGTGAGGCATATCTTCC-3’

Drissen et al., 2005

Urod

5’-ATCCCTGTGCCTTGTATGCA-3’
5’-AGGTTGGCAATTGAGCGTTG-3’

Drissen et al., 2005

Cpox

5’-CAATTTGAAGCCAGTCCGTG-3’
5’-CTGGACTAGAACTCCCTTTG-3’

Drissen et al., 2005

Ppox

5’-ATTCCAGCTTCAGAGCTCAG-3’
5’-TACTGCAGATTCACCACAGC-3’

Drissen et al., 2005

Fech

5’-ACCAGTGACCACATTGAGAC-3’
5’-GGCCTTGGAGAACAATGGAT-3’

Drissen et al., 2005

AHSP

5’-GGATCAGCAGGTCTTTGATG-3’
5’-AGAGTACTCAGCTCTTGCTG-3’

Drissen et al., 2005
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Table A.5 (continued).
Gene

Primer sequence

Reference

Epb4.9

5’-TGCTCAAGACCCAAGGCTTA-3′
5’-TCCTATCTGGTTTTGCCTGG-3′

Drissen et al., 2005

GAPDH

5’-CCTGCCAAGTATGATGACAT-3′
5’-GTCCTCAGTGTAGCCCAAG-3′

Drissen et al., 2005

Ankyrin

5’-CTCCAGCCGGACCTGATAGAG-3′
5′-GAACACGTGCGACCCTTCAGTAG-3′

Nilson et al., 2006

Band 3

5′-CACAGTGCCTCTCCGTCGTCTCATC-3′
5′-CCTTCCCCACCCACAGCCATAACAC-3′

Nilson et al., 2006

BKLF

5’-GAAATGTCACCCCCTTTAATGAAC-3′
5’-CACGATGACGGAAGGATGGT-3′

Funnell et al., 2007

Fli-1

5’-CAACCAGCCAGTGAGAGTCA-3′
5’-GCCCACCAGCTTGTTACATT-3′

β-globin mRNA

5’-TTTAACGATGGCCTGAATCACTT-3′
5’-CAGCACAATCAGATCATATTGC-3′

β-globin 1o transcripts

5’-CTTCTCTCTCTCCTCTCTCTTTCTCTAATC-3′
5’-AATGAACTGAGGGAAAGGAAAGG-3′
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Figure A.3. Fetal liver hematopoietic progenitors. Fetal liver cells were plated in
methocellulose medium and colonies were scored after 14 days of growth. Panels a-c:
burst-forming unit-erythroid (BFU-E). Panels d-f: colony-forming unit-granulocytemonocyte (CFU-GM). Panels g-i: colony-forming unit-granulocyte-erythroid-monocytemegakaryocyte.
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